EDAP TMS (EDAP) 20-F 7 Apr 21 2020 FY Annual report (foreign) Financial data

Document And Entity Information

Document And Entity Information	12 Months Ended
	Dec. 31, 2020shares
Document Information [Line Items]
Document Type	20-F
Document Registration Statement	false
Document Annual Report	true
Document Period End Date	Dec. 31, 2020
Document Transition Report	false
Document Shell Company Report	false
Entity File Number	000-29374
Entity Registrant Name	EDAP TMS SA
Entity Incorporation, State or Country Code	I0
Entity Address, Address Line One	Parc d’Activites la Poudrette-Lamartine
Entity Address, Address Line Two	4/6, rue du Dauphiné
Entity Address, Postal Zip Code	69120
Entity Address, City or Town	Vaulx-en-Velin
Entity Address, Country	FR
Entity Central Index Key	0001041934
Entity Common Stock, Shares Outstanding (in shares)	29,165,316
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Document Accounting Standard	U.S. GAAP
Entity Shell Company	false
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2020
Document Fiscal Period Focus	FY
Amendment Flag	false
Business Contact
Document Information [Line Items]
Entity Address, Address Line One	Parc d’Activites la Poudrette-Lamartine
Entity Address, Address Line Two	4/6, rue du Dauphiné
Entity Address, Postal Zip Code	69120
Entity Address, City or Town	Vaulx-en-Velin
Entity Address, Country	FR
Contact Personnel Name	Ms. Blandine Confort
City Area Code	33
Local Phone Number	4 72 15 31 50
Contact Personnel Email Address	bconfort@edap-tms.com

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Current assets
Cash and cash equivalents	€ 24,696	€ 20,886
Current portion of net trade accounts and notes receivable	11,307	11,328
Other receivables	1,031	1,259
Inventories	7,989	8,178
Other assets, current portion	369	447
Total current assets	45,393	42,097
Non-current assets
Property and equipment, net	3,704	4,069
Operating lease right-of-use assets	1,895	2,647
Intangible assets, net	761	770
Goodwill	2,412	2,412
Deposits and other non-current assets	655	640
Deferred tax assets	374	432
Net Trade accounts and notes receivable, non-current		2
Total assets	55,193	53,068
Current liabilities
Trade accounts and notes payable	5,708	6,046
Deferred revenues, current portion	2,701	1,892
Social security and other payroll withholdings taxes	1,176	1,207
Employee absences compensation	698	634
Income taxes payable	129	280
Other accrued liabilities	2,774	2,109
Short-term borrowings	2,638	3,513
Current obligations under finance leases	344	392
Current portion of operating lease obligations	802	958
Current portion of long-term debt	4,532	462
Total current liabilities	21,504	17,493
Non-current liabilities
Deferred revenues, non-current	926	1,313
Obligations under finance leases	555	653
Operating lease obligations, non-current	1,099	1,726
Long-term debt, non-current	1,143	957
Other long-term liabilities	3,720	3,567
Total liabilities	28,945	25,710
Shareholders' equity
Common stock, 0.13 par value; 29,457,744 shares issued and 29,165,316 shares outstanding at December 31, 2020; 0.13 par value; 29,433,994 shares issued and 29,141,566 shares outstanding at December 31, 2019	3,830	3,826
Additional paid-in capital	66,548	66,331
Retained earnings	(40,139)	(38,435)
Cumulative other comprehensive loss	(3,064)	(3,436)
Treasury stock, at cost; 292,428 at December 31, 2020 and at December 31, 2019	(928)	(928)
Total shareholders' equity	26,248	27,359
Total liabilities and shareholders' equity	€ 55,193	€ 53,068

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - € / shares	Dec. 31, 2020	Dec. 31, 2019
CONSOLIDATED BALANCE SHEETS
Common stock, par value	€ 0.13	€ 0.13
Common stock, shares issued	29,457,744	29,433,994
Commons stock, shares outstanding	29,165,316	29,141,566
Treasury stock	292,428	292,428

CONSOLIDATED STATEMENTS OF INCO

CONSOLIDATED STATEMENTS OF INCOME (LOSS) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues	€ 41,662	€ 44,912	€ 39,183
Cost of sales	(23,283)	(23,909)	(22,266)
Gross profit	18,379	21,002	16,917
Research and development expenses	(4,496)	(3,728)	(4,088)
Selling and marketing expenses	(9,279)	(10,850)	(10,551)
General and administrative expenses	(4,335)	(4,224)	(3,593)
Income (loss) from operations	269	2,201	(1,315)
Financial (expense) income, net	(98)	(146)	797
Foreign currency exchange gain (loss), net	(1,359)	136	538
Income (loss) before taxes	(1,188)	2,191	20
Total	(516)	(679)	(358)
Net income (loss)	€ (1,704)	€ 1,512	€ (338)
Basic income (loss) per share (in EUR per share)	€ (0.06)	€ 0.05	€ (0.01)
Diluted income (loss) per share (in EUR per share)	€ (0.06)	€ 0.05	€ (0.01)
Basic Weighted average shares outstanding (in shares)	29,148,108	29,016,118	28,997,866
Diluted Weighted average shares outstanding (in shares)	29,148,108	29,615,466	28,997,866
Product
Revenues	€ 41,649	€ 44,859	€ 39,163
Goods
Revenues	27,523	30,111	25,070
Cost of sales	(14,951)	(15,442)	(14,053)
RPP's and leases
Revenues	4,745	5,747	5,086
Cost of sales	(2,601)	(3,000)	(2,557)
Spare parts and services
Revenues	9,382	9,001	9,007
Cost of sales	(5,732)	(5,467)	(5,655)
Other revenues
Revenues	€ 12	€ 52	€ 19

CONSOLIDATED STATEMENTS OF COMP

CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS)
Net income (loss)	€ (1,704)	€ 1,512	€ (338)
Foreign currency translation adjustments	410	(61)	(146)
Provision for retirement indemnities	(38)	374
Comprehensive income (loss), net of tax	€ (1,332)	€ 1,825	€ (483)

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS EQUITY - EUR (€) € in Thousands	Common stock	Additional paid-in capital	Retained Earnings / (Loss)	Other comprehensive income (loss)	Treasury stock	Total
Balance at Dec. 31, 2017	€ 3,818	€ 65,694	€ (39,608)	€ (3,604)	€ (1,142)	€ 25,158
Balance (in shares) at Dec. 31, 2017	28,997,866
Net (loss) / income			(338)			(338)
Translation adjustment				(146)		(146)
Warrants and stock options granted or exercised		289				289
Balance (in shares) at Dec. 31, 2018	28,997,886
Balance at Dec. 31, 2018	€ 3,818	65,983	(39,947)	(3,748)	(1,142)	24,964
Net (loss) / income			1,512			1,512
Translation adjustment				(61)		(61)
Warrants and stock options granted or exercised		232				232
Capital increase	€ 8	116				124
Capital increase (in shares)	65,600
Treasury stock disposition					214	214
Treasury stock disposition (in shares)	78,100
Provision for retirement indemnities				374		374
Balance (in shares) at Dec. 31, 2019	29,141,566
Balance at Dec. 31, 2019	€ 3,826	66,331	(38,435)	(3,436)	(928)	27,359
Net (loss) / income			(1,704)			(1,704)
Translation adjustment				410		410
Warrants and stock options granted or exercised		160				160
Capital increase	€ 3	57				60
Capital increase (in shares)	23,750
Provision for retirement indemnities				(38)		(38)
Balance (in shares) at Dec. 31, 2020	29,165,316
Balance at Dec. 31, 2020	€ 3,830	€ 66,548	€ (40,139)	€ (3,064)	€ (928)	€ 26,248

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Cash flows from operating activities
Net income (loss)	€ (1,704)	€ 1,512	€ (338)
Adjustments to reconcile net income (loss) to net cash generated by (used in) operating activities:
Depreciation and amortization	2,105	1,879	1,610
Change in warrants fair value			(889)
Other non-cash compensation	160	260	289
Change in allowances for doubtful accounts & slow-moving inventories	734	176	591
Change in long-term provisions	455	(6)	300
Net capital loss on disposals of assets	291	79	37
Deferred tax expense (benefit)	45	(106)	(153)
Operating cash flow	2,087	3,794	1,447
Increase/Decrease in operating assets and liabilities:
Decrease (Increase) in trade accounts and notes and other receivables	1,137	908	(983)
Decrease (Increase) in inventories	(554)	(1,036)	(704)
Decrease (Increase) in other assets	69	(60)	115
(Decrease) Increase in trade accounts and notes payable	(422)	(249)	(70)
(Decrease) Increase in accrued expenses, other current liabilities	(339)	445	370
Net change in operating assets and liabilities	(110)	6	(1,272)
Net cash generated by (used in) operating activities	1,977	3,800	175
Cash flows from investing activities:
Additions to capitalized assets produced by the Company	(1,339)	(1,020)	(827)
Proceeds from sale of leased back assets			359
Acquisitions of property and equipment	(531)	(396)	(604)
Acquisitions of intangible assets	(103)	(35)	(438)
Acquisitions of other financial assets	(2)	(14)
Increase in deposits and guarantees	(36)	(67)	(59)
Net cash generated by (used in) investing activities	(2,011)	(1,532)	(1,569)
Cash flow from financing activities:
Proceeds from stock-option exercise	60	310
Proceeds from long term borrowings, net of financing costs	4,848	688	1,032
Repayment of long term borrowings	(519)	(1,087)	(443)
Repayment of obligations under financing leases in 2020 and 2019 and capital leases in 2018	(321)	(396)	(358)
Increase (decrease) in bank overdrafts and short-term borrowings	(867)	(179)	946
Net cash generated by (used in) financing activities	3,201	(664)	1,178
Net effect of exchange rate changes on cash and cash equivalents	642	(182)	(323)
Net increase (decrease) in cash and cash equivalents	3,810	1,422	(539)
Cash and cash equivalents at beginning of year	20,886	19,464	20,004
Cash and cash equivalents at end of year	€ 24,696	€ 20,886	€ 19,464

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	12 Months Ended
	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	1— SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 1-1 EDAP TMS S.A. and its subsidiaries (‘‘the Company’’) are engaged in the development, production, marketing, distribution and maintenance of a portfolio of minimally-invasive medical devices for the treatment of urological diseases. The Company currently produces innovative robotic devices for treating stones of the urinary tract and localized prostate cancer. We also derive revenues from the distribution of urodynamics products and urology lasers. Net sales consist primarily of direct sales to hospitals and clinics in France and Europe, export sales to third-party distributors and agents, and export sales through subsidiaries based in Germany, Italy, the United States and Asia. The Company purchases the majority of the components used in its products from a number of suppliers but for some components, relies on a single source. Delay would be caused if the supply of these components or other components was interrupted and these delays could be extended in certain situations where a component substitution may require regulatory approval. Failure to obtain adequate supplies of these components in a timely manner could have a material adverse effect on the Company’s business, financial position and results of operations. Since the occurrence in 2020 of the COVID-19 virus, we have taken steps to require the majority of our employees to work remotely, maintain minimum supply chain and development activity and curtail most business travels. The pandemic has resulted in further postponement and/or cancelation of the sale and installation of new devices and disposables in hospitals or clinics as investment decisions are put on hold or their resources are refocused on COVID-19. During this period, we benefited from covid related assistance loans from French, Japanese and US authorities. 1-2 These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP). 1-3 The preparation of financial statements in conformity with U.S. generally accepted accounting principles (‘‘U.S. GAAP’’) requires management to make estimates and assumptions, such as business plans, stock price volatility, duration of standard warranty per market, duration and interest rate of operating leases, price of maintenance contract used to determine the amount of revenue to be deferred and life duration of our range of products. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In particular regarding the estimate of future sales in our business plans, the prolonged impact of the COVID19 pandemic and lack of visibility on the return to normal sales cycles has created a higher level of uncertainty. Actual results could differ from those estimates. 1-4 The accompanying consolidated financial statements include the accounts of EDAP TMS S.A. and all its domestic and foreign owned subsidiaries after elimination of intercompany balances and transactions. We do not have any significant interests in any variable interest entities. 1-5 The Company adopted ASC Topic 606, Revenue from Contracts with Customers The Company’s revenue consists of: - Sales of goods (devices and consumables), where invoicing generally takes place upon delivery. Consumables revenues included in sales contract are deferred until delivery. - Revenue-per-Procedures (“RPP”) and leases: they comprise (i) - Sales of spare parts and services (maintenance, upgrades, mobility and others). Spare parts are invoiced when delivered. Regarding services, invoicing is performed either on a subscription basis (in advance or at the end of the period) or when performed. Sales of our medical devices and sales of disposables, sales of RPPs and leases, and sales of spare parts and services, are all net of commissions. The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due between one to three The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the goods or services and their payment terms can be identified, the contract has commercial substance, collectability of the contract consideration is probable, it is approved and the parties are committed to their obligations. Our sale arrangements may contain multiple elements, including device(s), consumables and services. For these multiple-element arrangements, the Company accounts for individual goods and services as separate performance obligations: (i) For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the goods or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the goods and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary. The Company recognizes revenue when the performance obligations are satisfied by transferring control over the goods or service to a customer. The Company’s revenue consists of the following: Sales of goods: Sales of goods are and have historically been comprised of sales net of commission of medical devices (ESWL lithotripters and HIFU devices) and net sales of disposables (mostly Ablapaks and Focalpaks in the HIFU division and electrodes in the ESWL division). Sales of goods also includes products such as urology laser and urodynamics devices distributed through our agents and third-party distributors. For devices and disposables, revenue is recognized when the Company transfers control to the customer (i.e. when the customer has the ability to direct the use of, and obtain substantially all of the remaining benefit from, the device or disposables), which is generally at the point of delivery or installation, depending on the terms of the arrangement (i.e. when the customer can use the goods to provide services or sell or exchange the good), and based on contractual incoterms. Such installation-related costs are immaterial in the context of the contract with the customer and do not constitute a distinct performance obligation. The Company’s sales arrangements do not provide a right of return. The goods are generally covered by a period of one to two Sales of RPPs and leases: Sales of RPP and leases include the revenues from the sale of treatment procedures and from the leasing of machines. For RPP, we provide machines to clinics and hospitals for free for a limited period, rather than selling the devices. These hospitals and clinics perform treatments using the devices and usually pay us based on the number of individual treatments provided. Revenues from leasing of machine are considered as immaterial. Revenues related to the sale of treatments invoiced on a ‘‘Revenue-Per-Procedure’’ (‘‘RPP’’) basis are recognized when the treatment procedure has been completed. Revenues from devices leased to customers under operating leases are recognized on a straight-line basis. Regarding multiple-element arrangements with a lease component, a portion of the contract is allocated to the lease component on the basis of observable market prices applied by the Company for similar devices under operating leases. The lease component is recognized on a straight line basis over the contractual period. Other immaterial components under the contract are recognized in accordance with their nature. Sales of spare parts and services: Revenues related to spare parts are recognized when spare parts are delivered to distributors who perform their own maintenance services. Spare parts used in the performance of EDAP’s own maintenance and repair services are generally not recognized separately, unless a type of spare part is specifically excluded from the maintenance contract terms. Revenues related to Services mainly consist of maintenance contracts which rarely exceed one The Company recognizes revenue for extended warranties included in the multiple-element arrangements as a separate performance obligation in Sales of services on a straight-line basis over the extended warranty period. In the majority of countries in which the Company operates, the statutory warranty period is one to two Agents and distributors: As part of its sale process in countries other than continental France, when the Company does not have a local subsidiary, sales of goods to end-customers are performed through agents and distributors. Such agents and distributors are primarily responsible for the sales’ process, bear the inventory risk, and are free to determine the sale prices. Sales of goods to agents and distributors are recognized when the control is transferred to the related agent or distributor which generally occurs based on contractual incoterms. Deferred revenue: Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed, and consists primarily of billing or cash receipts in advance of services due under maintenance contracts or extended warranty contracts. The associated deferred revenue is generally recognized ratably over the service period. Disaggregation of revenue: Disaggregation by primary geographical market, and timing of revenue recognition is reported in Note Contract Balances: Details on contract liabilities are reported on Note The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one 1-6 Costs of sales include all direct product costs, costs related to shipping, handling, duties and importation fees, as well as certain indirect costs such as service and supply chain departments expenses. Indirect costs are allocated by type of sales (goods, RPP and leases, spare parts and services) using an allocation method determined by management by type of costs and segment activities and reviewed on an annual basis. 1-7 Shipping and handling costs are not considered as performance obligations. Shipping and handling costs are recorded as a component of cost of sales. 1-8 Cash equivalents are cash investments which are highly liquid and have initial maturities of 90 Cash investments with a maturity higher than 90 1-9 The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and the Company’s customers’ financial condition, the amount of receivables in dispute, and the current receivables aging and current payment patterns. The Company reviews its allowance for doubtful accounts 1-10 Inventories are valued at the lower of cost and net realizable value. Cost is either the manufacturing cost, which is principally comprised of components and labor costs for our own manufactured products, or purchase price for urology products we distribute. Cost is determined on a first-in, first-out basis for components and spare parts and by specific identification for finished goods (medical devices). The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow moving, first based on a detailed comparison between quantity in inventory and historical consumption and then based on case-by-case analysis of the difference between the cost of inventory and the related estimated market value. 1-11 Property and equipment is stated at historical cost, net of accumulated depreciation and impairment. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful life of the related assets, as follows: ​ ​ ​ ​ ​ ​ ​ ​ Leasehold improvements (in years) ​ ​ 10 or lease term if shorter ​ ​ Equipment (in years) 3 — 10 Furniture, fixtures, fittings and other (in years) 2 ​ — 10 ​ Equipment includes industrial equipment and research equipment that has alternative future uses. Equipment also includes devices that are manufactured by the Company and leased to customers through operating leases related to Revenue-Per-Procedure transactions and devices subject to sale and leaseback transactions. This equipment is depreciated over a period of seven years. 1-12 The Company reviews the carrying value of its long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be fully recoverable. Recoverability of long-lived assets is assessed by a comparison of the carrying amount of the assets (or the Group of assets, including the asset in question, that represents the lowest level of separately-identifiable cash flows) to the total estimated undiscounted cash flows expected to be generated by the asset or group of assets. If the future net undiscounted cash flows is less than the carrying amount of the asset or group of assets, the asset or group of assets is considered impaired and an expense is recognized equal to the amount required to reduce the carrying amount of the asset or group of assets to its then fair value. Fair value is determined by discounting the cash flows expected to be generated by the assets, when the quoted market prices are not available for the long-lived assets. Estimated future cash flows are based on assumptions and are subject to risk and uncertainty. 1-13 Goodwill represents the excess of purchase price over the fair value of identifiable net assets of businesses acquired. Goodwill is not amortized but instead tested annually for impairment or more frequently when events or change in circumstances indicate that the assets might be impaired. When imparement indicators are identified, the impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, including goodwill. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. For the purpose of any impairment test, the Company relies upon projections of future undiscounted cash flows and takes into account assumptions regarding the evolution of the market and its ability to successfully develop and commercialize its products. Changes in market conditions could have a major impact on the valuation of these assets and could result in additional impairment losses. Intangible assets consist primarily of purchased patents relating to lithotripters, purchased licenses, a purchased trade name and a purchased trademark. The basis for valuation of these assets is their historical acquisition cost. Amortization of intangible assets is calculated by the straight-line method over the shorter of the contractual or estimated useful life of the assets, as follows: ​ ​ ​ ​ Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7 ​ 1-14 Treasury stock purchases are accounted for at cost. The sale of treasury stocks is accounted for using the first in first out method. Gains on the sale or retirement of treasury stocks are accounted for as additional paid-in capital whereas losses on the sale or retirement of treasury stock are recorded as additional paid-in capital to the extent that previous net gains from sale or retirement of treasury stocks are included therein; otherwise the losses shall be recorded to accumulated benefit (deficit) account. Gains or losses from the sale or retirement of treasury stock do not affect reported results of operations. Treasury stocks held by a Company cannot exceed 10% of the total number of shares issued. 1-15 The Company provides customers with a warranty for each product sold and accrues warranty expense at time of sale based upon historical claims experience. Standard warranty period may vary from 1 1-16 The Company accounts for income taxes in accordance with ASC 740, ‘‘Accounting for Income Taxes’’ Under ASC 740, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured by applying enacted tax rates and laws to taxable Under ASC740, the measurement of a tax position that meets the more-likely-that-not recognition threshold must take into consideration the amounts and probabilities of the outcomes that could be realized upon ultimate settlement using the facts, circumstances and information available at the reporting date. 1-17 Research and development costs are recorded as an expense in the period in which they are incurred. The French government provides tax credits to companies for innovative research and development. This tax credit is calculated based on a 1-18 Advertising costs are recorded as an expense in the period in which they are incurred and are included in selling and administrative expenses in the accompanying consolidated statements of income (loss). Advertising costs amounted to €291 thousand, €739 thousand and €719 thousand for the 1-19 Translation of the financial statements of consolidated companies The reporting currency of EDAP TMS S.A. for all ● assets and liabilities are translated at year-end exchange rates; ● shareholders’ equity is translated at historical exchange rates (as of the date of contribution); ● statement of income (loss) items are translated at average exchange rates for the year; and ● translation gains and losses are recorded in a separate component of shareholders’ equity. Foreign currencies transactions Transactions involving foreign currencies are translated into the functional currency using the exchange rate prevailing at the time of the transactions. Receivables and payables denominated in foreign currencies are translated at Presentation in the Statement of Income (loss) Aggregate foreign currency transactions gains and losses are disclosed in a single caption in the Statement of Income (loss) under section “Foreign currency exchange gain (loss), net”. 1-20 Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted earnings per share reflects potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. The dilutive effects of the Company’s common stock options and warrants is determined using the treasury stock method to measure the number of shares that are assumed to have been repurchased using the average market price during the period, which is converted from U.S. dollars at the average exchange rate for the period. 1-21 ASC 815 requires the Company to recognize all of its derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must classify the hedging instrument, based upon the exposure being hedged, as fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation. Gains and losses from derivative instruments are recorded in the Statement of Income (loss). As of December 1-22 At December 1-23 The Company recorded outstanding warrants issued in March 2012, May 2013 and April 2016 as a liability. Pursuant to guidance of ASC 815-40-15-7(i), the Company determined that the said warrants could not be considered as being indexed to the Company’s own stock, on the basis that the exercise price of the warrants was determined in U.S. dollars while the functional currency of the Company is the Euro. Since December 31, 2018, there were no more warrants outstanding. 1-24 Leases as a Lessee In accordance with ASC 842, Leases, and as from January controls Leases are classified as either finance leases or operating leases. Substantially all our operating leases are comprised of office space leases, and substantially all our finance leases are comprised of office furniture and technology equipment. The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, plus prepaid lease payments, less any lease incentives received. All ROU assets are reviewed for impairment. For operating leases, the lease liability is initially measured at the present value of the unpaid lease payments at lease commencement date, discounted using the incremental borrowing rate for assets of same duration or characteristics. For finance leases the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective interest method For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Lease payments included in the measurement of the lease liability comprise the following: the fixed payments, including in-substance fixed payments over the lease term (which includes termination penalties the Company would owe if the lease term assumes the Company’s exercise of a termination option), variable lease payments that depend on an index or ratepayments for optional renewal periods where it is reasonably certain the renewal period will be exercised, the exercise price of an option to purchase the underlying asset if the company is reasonably certain to exercise the option, and amounts expected to be paymable under a Company provided residual value guarantee. Documentation of the discount rates used is provided by a credit simulation carried out by the bank for similar goods and duration. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expenses in the Company’s consolidated statements of income in the same line item as expenses arising from fixed lease payments (operating leases) or amortization of the ROU asset (finance leases). Our real estate leases generally include non-lease maintenance services. The consideration in the contract is allocated to the lease and non-lease components based on standalone selling prices. Some of our real estate leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement, and changes to index and rate-based variable lease payments are recognized in profit or loss in the period of the change. Variable payments that do not depend on an index or rate, such as rental payments based on the use of the underlying asset or property taxes and insurance reimbursement, are recorded as operating expense when incurred. Lease modifications result in remeasurement of the lease payments when that modification is not accounted for as a separate contract. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense. The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor . We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 Leases as a Lessor: A lessor shall classify a lease as a sales-type lease when the lease meets any of the following criteria at lease commencement: ● The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. ● The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. ● The lease term is for the major part of the remaining economic life of the underlying asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease. ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments in accordance with paragraph 842-10-30-5(f) equals or exceeds substantially all of the fair value of the underlying asset. ● The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. When none of the criteria are met: A lessor shall classify the lease as either a direct financing lease or an operating lease. A lessor shall classify the lease as an operating lease unless both of the following criteria are met, in which case the lessor shall classify the lease as a direct financing lease: ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments in accordance with paragraph 842-10-30-5(f) and/or any other third party unrelated to the lessor equals or exceeds substantially all of the fair value of the underlying asset; ● It is probable that the lessor will collect the lease payments plus any amount necessary to satisfy a residual value guarantee. 1-25 Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (ASU 2016-02), which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 "Leases." This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. The Company adopted the new standard as of January 1, 2019. The Company performed an analysis of all contracts to identify lease components or rights of use. The Company determined that the new standard mostly applies to leases for facilities situated in France, Japan and in the U.S. and for Company’s equipment, vehicles and IT equipment. The last category has been determined as being below the threshold and not material. The Company adopted ASC 842 using a modified retrospective transition approach for all leases existing at or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company adopted the new standard as of January 1, 2019 with practical expedients, and did not restate comparative prior periods. The adoption of ASC 842 had a material effect on our consolidated balance sheet, but did not materially affect the consolidated statement of income (loss). The most significant impact was the recognition of the operating lease right-of-use assets and the liability for operating leases. The accounting for finance leases (capital leases) was substantially unchanged. Accordingly, upon adoption, leases that were classified as operating leases under ASC 840 were classified as operating leases under ASC 842, and we recorded an adjustment of €3.5 million to operating lease right-of-use assets and the related lease liability in 2019 In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13, which changes the impairment model for most financial assets. This standard has been amended with codification improvements in ASU 2018-19, 2019-04, 2019-05, 2019-11. The new model uses a forward-looking expected loss method, which generally results in earlier recognition of allowances for losses. ASU 2016-13 was effective for annual and interim periods beginning after December 15, 2019 and early adoption was permitted for annual and interim periods beginning after December 15, 2018. The Company adopted ASU 2016-13 on January 1, 2020. The application of ASU 2016-3 did not have a significant impact on our accounts. In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.” This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance was effective for the Company in the first quarter of 2020. Early adoption was permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The application of ASU 2016-3 did not have a significant impact on our accounts.

CASH EQUIVALENTS

CASH EQUIVALENTS	12 Months Ended
	Dec. 31, 2020
CASH EQUIVALENTS
CASH EQUIVALENTS	2— CASH EQUIVALENTS Cash equivalents at December 31, 2020 and 2019 only comprise cash investments which are highly liquid and have initial maturities of 90 days or less. ​

TRADE ACCOUNTS AND NOTES RECEIV

TRADE ACCOUNTS AND NOTES RECEIVABLE, NET	12 Months Ended
	Dec. 31, 2020
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET	3— TRADE ACCOUNTS AND NOTES RECEIVABLE, NET Trade accounts and notes receivable consist of the following: ​ ​ ​ ​ ​ ​ ​ 2020 2019 Trade accounts receivable 11,363 11,807 Notes receivable 667 1,013 Less: allowance for doubtful accounts (722) (1,490) Total 11,307 11,330 Less current portion (11,307) (11,328) Total long-term portion — 2 ​ Notes Bad debt expenses amount to a net cost of €87 thousand, a net cost of €84 thousand and €362 thousand, respectively for the Long term portion consists of sales type leases of medical devices.

OTHER RECEIVABLES

OTHER RECEIVABLES	12 Months Ended
	Dec. 31, 2020
OTHER RECEIVABLES
OTHER RECEIVABLES	4— OTHER RECEIVABLES Other receivables consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2020 2019 Research and development tax credit receivable from the French State ​ 492 766 Value-added taxes receivable ​ 403 422 Other receivables from Government and public authorities ​ 64 26 Others ​ 72 46 Total ​ 1,031 1,259 ​

INVENTORIES

INVENTORIES	12 Months Ended
	Dec. 31, 2020
INVENTORIES
INVENTORIES	5— INVENTORIES ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2020 2019 Components, spare parts ​ 6,050 4,959 Work-in-progress ​ 226 584 Finished goods – own manufactured products ​ 1,283 1,737 Finished goods – distribution products ​ 1,994 1,981 Total gross inventories ​ 9,552 9,262 Less: allowance for slow-moving inventory and net realizable value ​ (1,563) (1,085) Total ​ 7,989 8,178 ​ The provision for slow moving inventory relates to components and spare parts. The allowance for slow moving inventory (excluding exchange rate impact), the increases in which are classified within cost of sales, amounted to a cost of €651 thousand for the

OTHER ASSETS

OTHER ASSETS	12 Months Ended
	Dec. 31, 2020
OTHER ASSETS
OTHER ASSETS	6— OTHER ASSETS Other assets consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2020 2019 Prepaid expenses, current portion ​ 369 447 Total ​ 369 447 ​ Prepaid expenses mainly consist of rental and future congresses and conferences expenses.

PROPERTY AND EQUIPMENT, NET

PROPERTY AND EQUIPMENT, NET	12 Months Ended
	Dec. 31, 2020
PROPERTY AND EQUIPMENT, NET
PROPERTY AND EQUIPMENT, NET	7— PROPERTY AND EQUIPMENT, NET Property and equipment consist of Property and equipment purchased or capitalized by the Company and finance leases for 2020 and 2019. 7-1 Property and equipment consist of the following: ​ ​ ​ ​ ​ ​ ​ 2020 2019 Equipment ​ 8,405 ​ 7,002 Furniture, fixture, and fittings and other 2,736 2,776 Total gross value 11,141 9,778 Less: accumulated depreciation and amortization (8,142) (6,644) Total 3,000 3,134 ​ Depreciation expense related to property and equipment amounted to €1,695 thousand, €1,511 thousand and €981 thousand for the Assets leased to customers: Capitalized costs on equipment leased to customers of €264 thousand and €342 thousand are included in property and equipment at December Depreciation expense on equipment leased to customer is included in total depreciation expense and amounted to €240 thousand, €23 thousand and €51 thousand, for the 7-2 Finance lease right-of-use assets in 2020 and previous ​ ​ ​ ​ ​ ​ ​ 2020 2019 Equipment 359 713 Vehicles and IT equipment 1,196 1,582 Total gross value 1,554 2,295 Less: accumulated depreciation and amortization 850 1,360 Total 704 935 ​ Depreciation expense related to finance lease right-of-use assets amounted to €401 thousand, €448 thousand and €386 for the The reduction to right-of-use assets resulting from reductions to finance lease obligations amounted €670 thousand and €122 thousand for the

OPERATING LEASE RIGHT-OF-USE AS

OPERATING LEASE RIGHT-OF-USE ASSETS	12 Months Ended
	Dec. 31, 2020
OPERATING LEASE RIGHT-OF-USE ASSETS
OPERATING LEASE RIGHT-OF-USE ASSETS	8— OPERATING LEASE RIGHT-OF-USE ASSETS Operating lease right-of-use assets consist of the following: ​ ​ ​ ​ ​ ​ ​ 2020 2019 Facilities 1,584 2,387 Equipment 237 58 Furniture, fixture, and fittings and other 74 202 Total net operating lease right of use 1,895 2,647 ​ The reduction to right-of-use assets resulting from reductions to operating lease obligations amounted to €931 thousand and €836 thousand for the Variable lease costs related to above contracts amounted to €101 thousand and €108 thousand for the Non-recognized lease liabilities for short term leases amounted to €71 thousand and €71 thousand for the

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	12 Months Ended
	Dec. 31, 2020
GOODWILL AND INTANGIBLE ASSETS
GOODWILL AND INTANGIBLE ASSETS	9— GOODWILL AND INTANGIBLE ASSETS As discussed in Note Following the change of reporting segments in 2020, the previous UDS goodwill amount has been split between ESWL and Distribution according to the fair value of each segment measured at December The Company completed the required annual impairment test in the fourth quarter of 2020. To determine the fair value of the Company’s reporting units, the Company used the discounted cash flow approach for each of the three reportable units. In all three cases, the fair value of the reporting unit was in excess of the reporting unit’s book value, which resulted in no goodwill impairment. Intangible assets consist of the following: ​ ​ ​ ​ ​ ​ ​ 2020 2019 Licenses 1,570 1,466 Trade name and trademark 412 427 Patents 412 412 Organization costs 225 320 Total gross value 2,619 2,625 Accumulated amortization for licenses (813) (699) Accumulated amortization for trade name and trademark (409) (424) Accumulated amortization for patents (412) (412) Accumulated amortization for organization costs (225) (320) Less: Total accumulated amortization (1,858) (1,855) Total 761 770 ​ Amortization expenses related to intangible assets amounted to €113 thousand, €113 thousand and €110 thousand, for the For the five coming ​ ​ ​ ​ ​ December 31, ​ 2020 2021 113 2022 106 2023 94 2024 87 2025 87 Total 488 ​

TRADE ACCOUNTS AND NOTES PAYABL

TRADE ACCOUNTS AND NOTES PAYABLE	12 Months Ended
	Dec. 31, 2020
TRADE ACCOUNTS AND NOTES PAYABLE
TRADE ACCOUNTS AND NOTES PAYABLE	10— TRADE ACCOUNTS AND NOTES PAYABLE Trade accounts and notes payable consist of the following: ​ ​ ​ ​ ​ ​ ​ 2020 2019 Trade accounts payable 5,708 6,034 Notes payable — 12 Total 5,708 6,046 ​ Trade accounts payable usually represent invoices with a due date of 90 Notes

DEFERRED REVENUES

DEFERRED REVENUES	12 Months Ended
	Dec. 31, 2020
DEFERRED REVENUES
DEFERRED REVENUES	11— DEFERRED REVENUES Deferred revenues consist of the following: ​ ​ ​ ​ ​ ​ ​ 2020 2019 Deferred revenues on maintenance contracts ​ 1,761 ​ 1,741 Deferred revenue on RPP ​ 255 ​ 243 Deferred revenue on sale of devices ​ 135 ​ 115 Deferred revenue on extension of warranty, included in sales contracts ​ 782 ​ 837 Deferred research and development grants ​ 693 ​ 269 Total ​ 3,627 ​ 3,205 Less long term portion ​ (926) ​ (1,313) Current portion ​ 2,701 ​ 1,892 ​ Deferred revenue on extension of warranty will be recognized over the following periods: ​ ​ ​ ​ ​ December 31, ​ 2020 2021 300 2022 314 2023 143 2024 18 2025 8 Total 782 ​ Changes in deferred revenue on extension of warranty are as follows: ​ ​ ​ ​ ​ Total Balance as of December 31, 2018 855 New extension of warranty 254 Recognition of revenue (272) Balance as of December 31, 2019 837 New extension of warranty 206 Recognition of revenue (261) Balance as of December 31, 2020 782 ​

OTHER ACCRUED LIABILITIES

OTHER ACCRUED LIABILITIES	12 Months Ended
	Dec. 31, 2020
OTHER ACCRUED LIABILITIES
OTHER ACCRUED LIABILITIES	12— OTHER ACCRUED LIABILITIES Other accrued liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ 2020 2019 Retirement indemnities 2,665 2,444 Provision for warranty costs 368 370 Accruals for payroll and associated taxes 734 738 Conditional government advances 1,097 1,071 Value added tax payable 420 557 Advances received from customers 551 — Provision for Asset Retirement Obligation (Japan) 113 117 Provision for employee termination indemnities (Korea) 69 56 Others 477 323 Total 6,494 5,676 Less non-current portion (3,720) (3,567) Current portion 2,774 2,109 ​ We receive government conditional advances and grants for advanced research programs we conduct alone or in connection with other unrelated entities (mainly HECAM project) which are provided for and managed by French state-owned entities, and specifically “Banque Publique d’Investissement” (“Bpifrance”). We, alone or with other unrelated entities, enter into multi-year contractual arrangements for the financing of specific research programs. These arrangements consist of both grants and conditional advances which are paid in fixed instalments at predetermined contractual dates, subject generally to milestones based on progress of the research and documentation. Grants received are non-refundable. Conditional advances received are subject to a fixed 1.44% interest rate. Despite a first mono-centric study successfully implemented with Lyon’s Centre Leon Bérard cancer center, we decided not to pursue the development of HIFU for liver cancer as a per-operative approach. The multi-centric Phase II study, which was to be initiated following the mono-centric study, will not be implemented. We considered that the per-operative approach initially targeted will not offer the breakthrough innovation expected by the market and will lead to comparative lengthy clinical studies with existing therapeutic solutions to fulfill the requirement of the new European MDR regulations to become effective in May In 2020, the Company decided to reorient the efforts, knowledge and assets resulting from the HECAM project in two directions. The first one, with a technology and approach very similar to the one developed for liver cancer, will focus on pancreatic cancer for patients with few or even no alternatives. The second one will still target liver cancer application but through an extracorporeal solution to offer to patients affected by primary or metastatic liver cancer an undisputable benefit compared to the existing alternatives. In 2021, the Company will discuss with BPI France whether the conditional advance may be repayable. Grants that relate to expenses we incur for this research program are recognized in the line item “Research and Development Expenses” in the period in which the expenses subject to the grants have been incurred (see Note Conditional advances as of December ​ ​ ​ ​ 2021 6 2022 214 2023 214 2024 214 2025 and thereafter 447 Total 1,097 ​ Changes in the provision for warranty costs are as follows: ​ ​ ​ ​ ​ ​ ​ 2020 2019 Beginning of year 370 547 Amount used during the year (268) (308) New warranty expenses 266 131 End of year 368 370 Less current portion (262) (260) Long term portion 106 110 ​

LEASE OBLIGATIONS

LEASE OBLIGATIONS	12 Months Ended
	Dec. 31, 2020
LEASE OBLIGATIONS
LEASE OBLIGATIONS	13— LEASE OBLIGATIONS 13-1 The Company leases certain of its equipment under finance leases. At December Maturities of finance leases liabilities for the ​ ​ ​ ​ ​ December 31, ​ 2020 2021 360 2022 280 2023 190 2024 72 2025 and thereafter 28 Total undiscounted minimum lease payments 930 Less: amount representing interest (33) Present value of minimum lease payments 899 Less: current portion (344) Long-term portion 555 ​ ​ ​ ​ ​ December 31, ​ 2019 2020 415 2021 299 2022 221 2023 122 2024 and thereafter 30 Total undiscounted minimum lease payments 1,086 Less: amount representing interest (41) Present value of minimum lease payments 1,044 Less: current portion (392) Long-term portion 653 ​ Interest paid under finance lease obligations was €33and €29 thousand the The weighted average remaining lease term and the weighted average discount rate for finance leases at December 13-2 Maturities of operating leases liabilities consist of the following amounts: ​ ​ ​ ​ ​ December 31, ​ 2020 2021 803 2022 523 2023 381 2024 195 2025 and thereafter — Total undiscounted minimum lease payments 1,901 Less: current portion (802) Long-term portion 1,099 ​ ​ ​ ​ ​ December 31, ​ 2019 2020 980 2021 758 2022 474 2023 349 2024 and thereafter 171 Total undiscounted minimum lease payments 2,732 Less: amount representing interest (48) Present value of minimum lease payments 2,684 Less: current portion ​ (958) Long-term portion ​ 1,726 ​ The weighted average remaining lease term and the weighted average discount rate for operating leases at December Total rent expenses under operating leases amounted to €941 thousand, €828 thousand and €1,002 thousand, for the

SHORT-TERM BORROWINGS

SHORT-TERM BORROWINGS	12 Months Ended
	Dec. 31, 2020
SHORT-TERM BORROWINGS
SHORT-TERM BORROWINGS	14— SHORT-TERM BORROWINGS As of December As of December

LONG TERM DEBT AND FINANCIAL IN

LONG TERM DEBT AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE	12 Months Ended
	Dec. 31, 2020
LONG TERM DEBT AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE
LONG TERM DEBT AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE	15— LONG TERM DEBT AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE 15-1 ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2020 2019 France term loan 4,394 351 Japanese term loan (YEN) 900 617 Germany term loan 193 438 USA term loan 180 — Malaysia term loan 8 13 Total long term debt 5,675 1,420 Less current portion (4,532) (462) Total long-term portion 1,143 957 ​ As of December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP Technomed Co. Ltd 80,000,000 ​ August 2, 2026 1.98 % Monthly instalment EDAP Technomed Co. Ltd 50,000,000 ​ April 2, 2025 1.8 % Monthly instalment ​ As of December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP Technomed Co. Ltd 80,000,000 ​ August 2, 2026 1.98 % Monthly instalment EDAP Technomed Co. Ltd 40,000,000 ​ April 15, 2020 2.91 % Monthly instalment ​ The long-term debt of 40,000,000 has been fully reimbursed in April As of December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS GMBH 400,000 ​ April 30, 2023 2.40 % Monthly instalment ​ This loan was pledged against an HIFU equipment with a purchase value of €438 thousand. As of December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS GMBH 136,500 ​ December 31, 2022 2.25 % Monthly instalment ​ This loan is pledged against a ESWL equipment with a purchase value of €136 thousand. This loan has been fully reimbursed in last quarter of 2020. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS GMBH 450,000 ​ November 30, 2020 2.49 % Monthly instalment ​ This loan was pledged against an HIFU equipment with a purchase value of €450 thousand, it has been fully reimbursed in November As of December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 700,000 ​ October 16, 2021 0.40 % Quarterly instalment ​ This loan is related to ERP SAP project. This four-year loan will be fully reimbursed in October 2021. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 218,000 ​ April 1, 2025 0.99 % Monthly instalment ​ This new loan is pledged against the countervalue in dollars on the loan. This loan constitutes a complete financial package of €1,530,000, of which €218,000 was drawn at the end of December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ August 11, 2021 0.25 % Monthly instalment ​ This new loan is COVID-related loan guaranteed by the French government with initially one ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ August 4, 2021 0.25 % Monthly instalment ​ This new loan is COVID-related loan guaranteed by the French government with initially one As of December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 700,000 ​ October 16, 2021 0.40 % Quarterly instalment ​ As of December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TECHNOMED SDN BHD 90,000 ​ July 31, 2022 4.64 % Monthly instalment ​ As of December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TECHNOMED INC 221,217 ​ May 14, 2022 1 % Monthly instalment ​ This loan has been received from the US Paycheck Protection Program and may be forgivable in the future if certain conditions are met. 15-2 As of December Refer to Note 15-3 Long-term debt carried at fair value at December ​ ​ ​ ​ 2021 4,532 2022 504 2023 228 2024 200 2025 and thereafter 210 Total 5,675 ​

OTHER LONG-TERM LIABILITIES

OTHER LONG-TERM LIABILITIES	12 Months Ended
	Dec. 31, 2020
OTHER LONG-TERM LIABILITIES
OTHER LONG-TERM LIABILITIES	16— OTHER LONG-TERM LIABILITIES Other long-term liabilities consist of the following: ​ ​ ​ ​ ​ ​ ​ 2020 2019 Provision for retirement indemnities (Japan & France), less current portion 2,273 2,167 Provision for employee termination indemnities (Korea) less current portion 69 56 Provision for Asset Retirement Obligation (Japan) less current portion 113 117 Provision for warranty costs, less current portion 106 110 Conditional government advances, less current portion 1,097 1,071 Accrued interest less current portion 62 46 Total 3,720 3,567 ​ Provision for asset retirement obligation in Japan is related to subsidiary’s offices and warehouses. Pension, post-retirement and post-employment benefits for most of the Company’s employees are sponsored by European governments. In addition to government-sponsored plans, subsidiaries in Japan and France have defined benefit retirement indemnity plans in place. The provision for retirement indemnities at December The provision is management’s best estimate based on the following assumptions as of ​ ​ ​ ​ ​ ​ ​ ​ Pension benefits France ​ ​ 2020 ​ 2019 Discount rate 0.60 % 0.90 % Salary increase 2.50 % 2.50 % Retirement age 65 65 ​ Average retirement remaining service period 24 24 ​ ​ ​ ​ ​ ​ ​ ​ ​ Pension benefits Japan ​ ​ 2020 ​ 2019 Discount rate 0.60 % 0.60 % Salary increase 2.50 % 2.50 % Retirement age 60 60 ​ Average retirement remaining service period 14 14 ​ ​ The discount rate retained is determined by reference to the high quality rates for AA- rated corporate bonds for a duration equivalent to that of the obligations. It derives from a benchmark per monetary area of different market data at the closing date. In 2020, provision presentation according to ASC 715 in thousands of euros ​ ​ ​ ​ ​ ​ ​ France Japan Non-current liabilities ​ 1,032 ​ 1,241 Current liabilities 80 69 Accumulated other comprehensive income (loss) (111) (130) Total 1,000 1,181 ​ In 2019, provision presentation according to ASC 715 in thousands of euros: ​ ​ ​ ​ ​ ​ ​ France Japan Non-current liabilities ​ 960 ​ 1,207 Current liabilities 10 22 Accumulated other comprehensive income (loss) (67) (136) Total 903 1,093 ​ The Company does not have a funded benefit plan. Detailed reconciliation of pension cost components (in thousands of euros) during fiscal ​ ​ ​ ​ ​ ​ ​ ​ France 2020 2019 2018 Change in benefit obligations: Benefit obligations at beginning of year 969 976 895 Service cost 88 68 67 Interest cost 9 16 14 Net loss or (gain) — 2 — Actuarial (gain) or loss 45 (93) ​ ​ Amortization of net prior service cost 1 1 1 Benefits paid — — — Benefit obligations at end of year (1) 1,111 969 976 Unrecognized actuarial (gain) loss (2) 94 48 141 Unrecognized prior service cost (2) 17 18 20 Accrued pension cost 1,000 903 815 (1) The accumulated benefit obligation was €800 thousand and €693 thousand at December 31, 2020 and 2019 respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2020 is €1 thousand. ​ ​ ​ ​ ​ ​ ​ ​ Japan 2020 2019 2018 Change in benefit obligations: Benefit obligations at beginning of year 1,230 1,311 1,182 Service cost 123 140 131 Interest cost 7 6 6 Amortization of net loss 1 27 26 Actuarial (gain) / loss (1) (294) — Benefits paid (5) (3) (94) Exchange rate impact (44) 42 (60) Benefit obligations at end of year (1) 1,310 1,230 1,311 Unrecognized actuarial (gain) loss (2) 130 136 416 Unrecognized prior service cost (2) — — — Accrued pension cost 1,181 1,093 895 (1) The accumulated benefit obligation was €1,134 thousand and €1,062 thousand at December 31, 2020 and 2019, respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2020 is €1 thousand. The benefits expected to be paid in each of the next five fiscal ​ ​ ​ ​ ​ ​ ​ France Japan 2021 80 70 2022 — 105 2023 67 114 2024 — 157 2025 — 167 2026-2030 318 397 ​ 465 1,008 ​

SHAREHOLDERS' EQUITY

SHAREHOLDERS' EQUITY	12 Months Ended
	Dec. 31, 2020
SHAREHOLDERS' EQUITY
SHAREHOLDERS' EQUITY	17— SHAREHOLDERS’ EQUITY 17-1 As of December 17-2 Shareholders have preemptive rights to subscribe on a pro rata 17-3 Dividends may be distributed from the statutory retained earnings, subject to the requirements of French law and the Company’s by-laws. The Company has not distributed any dividends since its inception as the result of an accumulated statutory deficit of €16,172 thousand. Dividend distributions, if any, will be made in euros. The Company has no plans to distribute dividends in the foreseeable future. 17-4 As of December 17-5 As of December As of December On December On February Conforming to this February Conforming to this February the total fair value of the options granted on August Conforming to this February The impact of this February Under this 2016 plan, 924,400 options are outstanding, 708,150 options are exercisable and 13,750 options are exercised at December On June Forfeited stock-options are recognized as they occur, in accordance with ASU 2016-09. The fair value of each stock option granted during the ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Weighted-average expected life (years) — (2) 6.25 6.25 ​ Expected volatility rates (1) — 49.45 % 52.6 % Expected dividend yield — 0 % 0 % Risk-free interest rate — (0.08) % 0.18 % Weighted-average exercise price (€) — 3.90 2.65 ​ Weighted-average fair value of options granted during the year (€) — 1.93 1.33 ​ (1) Historical volatility calculated over 10 years. ​ (2) There was no new plan for the year 2020. ​ As of December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 ​ 2018 ​ ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ exercice ​ ​ ​ exercice ​ ​ ​ exercice ​ Options price (€) Options price (€) Options price (€) Outstanding on January 1, 1,273,900 2.78 1,347,600 2.61 1,207,600 2.61 Granted — — 155,000 3.90 165,000 2.65 Exercised (23,750) 2.54 (143,700) 2.16 — — Forfeited (21,250) 2.55 (85,000) 1.94 (25,000) 3.05 Expired (42,000) 2.38 — — — — Outstanding on December 31, 1,186,900 2.81 1,273,900 2.78 1,347,600 2.61 Exercisable on December 31, 970,650 2.73 818,900 2.60 772,600 2.44 Share purchase options available for grant on December 31, 292,428 ​ 250,428 250,428 ​ The following table summarizes information about options to purchase existing Shares held by the Company, or to subscribe to new Shares, at December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding options ​ Fully vested options (1) ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ average ​ Aggregate ​ ​ ​ average ​ Aggregate ​ ​ ​ ​ remaining ​ exercise ​ Intrinsic ​ ​ ​ exercise ​ Intrinsic ​ ​ ​ ​ contractual ​ price ​ Value ​ ​ ​ price ​ Value Exercise price (€) Options life (€) (2) Options (€) (2) 3.90 130,000 8.8 3.90 42,576 32,500 3.90 13,017 3.22 465,000 5.3 3.22 468,492 465,000 3.22 468,492 2.65 145,000 7.7 2.65 228,739 72,500 2.65 114,369 2.39 184,400 6.3 2.39 338,837 138,150 2.39 253,852 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1.91 262,500 2.0 1.91 608,346 262,500 1.91 608,346 1.91 to 3.90 1,186,900 6.0 2.81 1,686,989 970,650 2.73 1,458,076 (1) Fully vested options are all exercisable options. (2) The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $5.17 at December 31, 2020, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date. A summary of the status of the non-vested options to purchase shares or to subscribe to new shares as of December ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average ​ ​ ​ ​ Grant-Date Fair ​ Options Value (€) Non-vested at January 1, 2018 ​ 593,750 ​ 1.53 Granted ​ 165,000 ​ 1.33 Vested ​ (180,000) ​ 1.56 Forfeited ​ (3,750) ​ 1.29 Non-vested at December 31, 2018 ​ 575,000 ​ 1.47 Non-vested at January 1, 2019 ​ 575,000 ​ 1.47 Granted ​ 155,000 ​ 1.93 Vested ​ (204,000) ​ 1.52 Forfeited ​ (70,600) ​ 1.58 Non-vested at December 31, 2019 ​ 455,000 ​ 1.58 Non-vested at January 1, 2020 455,000 1.58 Granted 0 0 Vested (235,000) 1.58 Forfeited (3,750) 1.54 Non-vested at December 31, 2020 216,250 1.59 ​ As of December 17-6 The components of accumulated other comprehensive income (loss) net of tax, for the ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2020 ​ ​ Foreign currency ​ ​ ​ ​ ​ ​ translation ​ Provision for ​ ​ ​ ​ adjustment ​ retirement indemnities ​ Total Beginning balance (3,234) (203) (3,436) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) 410 (38) 372 Ending balance (2,824) (241) (3,064) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2019 ​ ​ Foreign currency ​ ​ ​ ​ ​ ​ translation ​ Provision for ​ ​ ​ ​ adjustment ​ retirement indemnities ​ Total Beginning balance (3,173) (577) (3,748) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) (61) 374 313 Ending balance (3,234) (203) (3,436) ​ As there is an allowance recorded against deferred tax assets, there is no net impact of tax.

TOTAL SALES

TOTAL SALES	12 Months Ended
	Dec. 31, 2020
TOTAL SALES
TOTAL SALES	18— TOTAL SALES Amount of net sales derived from our operations in Asia, France, the United States. and other geographical areas, are as follows: ​ ​ ​ ​ ​ ​ ​ ​ Primary geographical markets (€) 2020 2019 2018 Asia 15,872 17,939 14,119 France 10,021 11,350 11,577 United States 5,611 5,194 2,048 Others geographical areas 10,146 10,377 11,419 ​ 41,649 44,859 39,163 ​ The amount of net sales is recognized following the timing above: ​ ​ ​ ​ ​ ​ ​ ​ Timing of revenue recognition 2020 2019 2018 Products transferred at a point in time 32,862 36,767 31,373 Products and services transferred over time 8,787 8,092 7,790 ​ 41,649 44,859 39,163 ​

OTHER REVENUES

OTHER REVENUES	12 Months Ended
	Dec. 31, 2020
OTHER REVENUES
OTHER REVENUES	19— OTHER REVENUES Other revenues consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Licenses and others 12 52 19 Total 12 52 19 ​ In 2020, 2019 and 2018, other revenues mainly consist of sales of a license to Theraclion and training to customers.

COSTS OF SALES

COSTS OF SALES	12 Months Ended
	Dec. 31, 2020
COSTS OF SALES
COSTS OF SALES	20— COSTS OF SALES Costs of sales consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Direct costs of sales (14,058) (14,919) (13,683) Indirect costs of sales (9,225) (8,990) (8,583) Total costs of sales (23,283) (23,909) (22,266) ​

RESEARCH AND DEVELOPMENT EXPENS

RESEARCH AND DEVELOPMENT EXPENSES	12 Months Ended
	Dec. 31, 2020
RESEARCH AND DEVELOPMENT EXPENSES
RESEARCH AND DEVELOPMENT EXPENSES	21— RESEARCH AND DEVELOPMENT EXPENSES Research and development expenses consist of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Gross research and development expenses (5,173) (4,727) (4,863) Research Tax Credit 492 762 685 Grants 184 236 90 Net Research and development expenses (4,496) (3,728) (4,088) ​ In 2020 and 2019 grants consisted mainly of national grants for the assessment and optimization of the focal treatments of prostate cancer (Perfuse development project). In 2018 grants mainly consisted of European, national and regional grants for the development of innovative imaging solutions for the focal treatment of liver cancer (HECAM Development project). Research and development costs are expensed as incurred and include amortization of assets, costs of prototypes, salaries, benefits and other headcount related costs, contract and other outside service fees, and facilities and overhead costs.

FINANCIAL INCOME, NET

FINANCIAL INCOME, NET	12 Months Ended
	Dec. 31, 2020
FINANCIAL INCOME, NET
FINANCIAL INCOME, NET	22— FINANCIAL INCOME, NET Interest (expense) income, net consists of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Interest income ​ 10 ​ 20 ​ 19 Interest expense (108) (165) (111) Warrants exercised / forfeited — — 889 Total (98) (146) 797 ​ ​ ​ ​ ​ ​ ​ ​

INCOME TAXES

INCOME TAXES	12 Months Ended
	Dec. 31, 2020
INCOME TAXES
INCOME TAXES	23— INCOME TAXES 23-1 Income / (loss) before income taxes is comprised of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 France ​ (2,042) ​ 1,803 ​ 1,687 Other countries 854 388 (1,667) Total (1,188) 2,191 20 ​ 23-2 Income tax (expense)/benefit consists of the following : ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Current income tax expense: ​ ​ ​ France (158) (237) (163) Other countries (312) (550) (351) Sub-total current income tax expense (471) (787) (515) Deferred income tax (expense) benefit: France 8 (1) 2 Other countries (53) 109 155 Sub-total deferred income tax (expense) benefit (45) 108 157 Total (516) (679) (358) ​ 23-3 Deferred income taxes reflect the impact of temporary differences between the amounts of assets and liabilities reported for financial reporting purposes and such amounts as measured in accordance with tax laws. The tax effects of temporary differences which give rise to significant deferred tax assets (liabilities) are as follows by nature ​ ​ ​ ​ ​ ​ ​ 2020 2019 Net operating loss carry forwards ​ 14,014 ​ 13,642 Elimination of intercompany profit in inventory 161 269 Elimination of intercompany profit in fixed assets 244 349 Provisions for retirement indemnities 634 577 Capital leases treated as operating leases for tax 56 29 Other items 775 544 Total deferred tax assets 15,883 15,410 Total deferred tax liabilities — — Net deferred tax assets 15,883 15,410 Valuation allowance for deferred tax assets (15,508) (14,977) Deferred tax assets (liabilities), net of allowance 374 432 ​ Net operating loss carryforwards available amounts to €59,052 thousand as of December The 2017 U.S. Tax Act was enacted on December Starting from tax 23-4 A reconciliation of differences between the statutory French income tax rate and the Company’s effective tax income (loss) is as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Theoretical tax income / (loss) at French statutory tax rate ​ 333 ​ (614) ​ (6) Income of foreign subsidiaries taxed at different tax rates 9 (51) (124) Effect of net operating loss carry-forwards and valuation allowances (858) 189 (210) Non-taxable debt fair value variation — — 235 Permanent differences (159) (251) (392) Effect of cancellation of intra-group positions 152 (54) 35 French business tax included in income tax (CVAE) (156) (159) (161) Other 164 263 265 Effective income (loss) tax (516) (679) (358) ​ 23-5 According to ASC 740, the Company reviewed the tax positions of each subsidiary. On December The Company remains subject to examination by major tax jurisdictions. Interest and penalties on income taxes are classified as a component of the provision for income taxes. There were no interest or penalties in 2020, 2019 and 2018.

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	12 Months Ended
	Dec. 31, 2020
EARNINGS (LOSS) PER SHARE
EARNINGS (LOSS) PER SHARE	24— EARNINGS (LOSS) PER SHARE ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 December 31, 2018 Income (loss) available to common shareholders (in Euros) ​ € (1,703,668) ​ € 1,512,056 ​ € (338,382) Number of shares for the computation of basic EPS ​ 29,148,108 ​ 29,016,118 ​ 28,997,866 Basic EPS (in Euros) ​ € (0.06) ​ € 0.05 ​ € (0.01) Effect of dilutive securities ​ 622,723 ​ 604,238 ​ 347,500 Number of shares for the computation of diluted EPS ​ 29,148,108 ​ 29,615,466 ​ 28,997,866 Diluted EPS income / (loss) (in Euros) ​ € (0.06) ​ € 0.05 ​ € (0.01) ​ Diluted EPS income / (loss) available to common shareholders is computed including all dilutive securities that are in the money. The effects of dilutive securities for the

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	12 Months Ended
	Dec. 31, 2020
COMMITMENTS AND CONTINGENCIES
COMMITMENTS AND CONTINGENCIES	25— COMMITMENTS AND CONTINGENCIES 25-1 The Company currently has commitments regarding its operating leases as described in Note 25-2 The Company currently has contingencies relating to warranties provided to customers for products as described in Note

FAIR VALUE OF FINANCIAL INSTRUM

FAIR VALUE OF FINANCIAL INSTRUMENTS	12 Months Ended
	Dec. 31, 2020
FAIR VALUE OF FINANCIAL INSTRUMENTS
FAIR VALUE OF FINANCIAL INSTRUMENTS	26— FAIR VALUE OF FINANCIAL INSTRUMENTS The following disclosure of the estimated fair value of financial instruments was made in accordance with the requirements of ASC 820 ‘‘Disclosure about fair value of financial instruments’’ and indicates the fair value hierarchy of the valuation techniques utilized to determine such fair value. ASC 820 defines three levels of inputs that may be used to measure fair value and requires that the assets or liabilities carried at fair value be disclosed by the input level under which they were valued. The input levels are defined as follows: Level 1: Quoted (unadjusted) prices in active markets for identical assets and liabilities that the reporting entity can access at the measurement date. Level 2: Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly. Level 3: Unobservable inputs for the asset or liability. ​ ​ ​ ​ ​ ​ ​ ​ ​ ASC 820 December December ​ ​ Level ​ 31, 2020 ​ 31, 2019 Assets: ​ ​ ​ Cash and cash equivalents Level 1 24,696 20,886 Liabilities: Short-term borrowings Level 1 2,638 3,513 Long-Term Debt Level 1 5,675 1,420 ​ The recorded amount of cash and cash equivalents and short-term borrowings are a reasonable estimate of their fair value due to the short-term maturities of these instruments. The fair market value (Level 1 measurement) of the Company’s long-term debt is estimated using interest rate available to the Company in corresponding markets for debt with similar terms and maturities (see note 15-1 Long-term debt).

CONCENTRATION OF CREDIT RISK

CONCENTRATION OF CREDIT RISK	12 Months Ended
	Dec. 31, 2020
CONCENTRATION OF CREDIT RISK
CONCENTRATION OF CREDIT RISK	27— CONCENTRATION OF CREDIT RISK Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents and trade accounts and notes receivable from customers, primarily located in France, Japan and the United States. The Company maintains cash deposits with major banks. Management periodically assesses the financial condition of these institutions and believes that credit risk is limited. The Company has implemented procedures to monitor the creditworthiness of its customers. The Company obtains bank guarantees for first time or infrequent customers, and in certain cases obtains insurance against the risk of a payment default by the customer. The Company reviewed individual customer balances considering current and historical loss experience and general economic conditions in determining the allowance for doubtful accounts receivable of €0.7 million and €1.5 million, for the Actual losses may vary from the current estimates, and any adjustments are reported in earnings in the periods in which they become known. In 2020, 2019 and 2018, the Company did not generate more than 10% revenue with a single customer.

FOREIGN CURRENCY TRANSACTIONS

FOREIGN CURRENCY TRANSACTIONS	12 Months Ended
	Dec. 31, 2020
FOREIGN CURRENCY TRANSACTIONS
FOREIGN CURRENCY TRANSACTIONS	28— FOREIGN CURRENCY TRANSACTIONS The Company generates a significant

SEGMENT INFORMATION

SEGMENT INFORMATION	12 Months Ended
	Dec. 31, 2020
SEGMENT INFORMATION
SEGMENT INFORMATION	29— SEGMENT INFORMATION We recently implemented organizational changes in our structure and realigned our activity into three divisions: HIFU, ESWL (including lithotripsy activities) and Distribution to better reflect how we view our businesses and how we measure our progress. Through these three divisions, we develop, produce, market and distribute minimally invasive medical devices, mainly for urological diseases. HIFU division includes sales of Focal One, Ablatherm and related consumables and services, ESWL division includes revenues generated by the existing Sonolith range of lithotripters and, Distribution division includes the sale of complimentary products such as lasers, micro-ultrasound systems and other products from third parties. The organization of our activities into three divisions better clarified our vision and enhanced our financial reporting of our three businesses HIFU, ESWL and Distribution. This new structure also allows for an improved measurement of our business progress. The business in which the Company operates is the development, production and distribution of minimally invasive medical devices, primarily for the treatment of urological diseases. Substantially all revenues result from the sale of medical devices and their related license and royalty payments from third parties. The segments derive their revenues from this activity. The following tables set forth the key Statement of income (loss) figures, by segment for fiscal ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Segment operating income (loss) 269 2,201 (1,315) Financial income (expense), net (98) (146) 797 Foreign Currency exchange (losses) gains, net (1,359) 136 538 Income tax (expense) credit (516) (679) (358) Consolidated net profit (loss) (1,704) 1,512 (338) ​ A summary of the Company’s operations by segment is presented below for ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2020 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 6,000 6,248 15,274 ​ ​ 27,523 Sales of RPPs & leases 3,594 927 224 ​ ​ 4,745 Sales of spare parts and services 1,831 5,707 1,844 ​ ​ 9,382 Total sales 11,425 12,882 17,342 ​ ​ 41,649 External other revenues 12 — — ​ ​ 12 Total revenues 11,438 12,882 17,342 ​ ​ 41,662 Total COS (5,144) (7,232) (10,906) ​ ​ (23,283) Gross profit 6,293 5,649 6,436 ​ ​ 18,379 R&D expenses (2,583) (1,555) (358) ​ ​ (4,496) Selling and marketing expenses (3,151) (2,052) (4,076) ​ ​ (9,279) G&A expenses (1,005) (964) (900) (1,465) (4,335) Total expenses (6,738) (4,572) (5,335) (1,465) (18,110) Operating income (loss) from operations (445) 1,078 1,102 (1,465) 269 Total Assets 16,279 15,567 20,795 2,551 55,193 Capital expenditures 1,144 309 557 — 2,011 Non-current assets 3,706 2,466 3,628 — 9,801 Goodwill 645 496 1,271 — 2,412 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2019 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 8,311 6,715 15,084 — 30,111 Sales of RPPs & leases 4,162 1,426 158 — 5,747 Sales of spare parts and services 1,618 6,048 1,335 — 9,001 Total sales 14,092 14,190 16,578 — 44,859 External other revenues 52 — — — 52 Total revenues 14,144 14,190 16,578 — 44,912 Total COS (6,152) (7,816) (9,941) — (23,909) Gross profit 7,991 6,374 6,637 — 21,002 R&D expenses (1,962) (1,394) (372) — (3,728) Selling and marketing expenses (4,402) (2,441) (4,008) — (10,850) G&A expenses (1,168) (904) (854) — (4,224) Total expenses (7,533) (4,738) (5,233) — (18,802) Operating income (loss) from operations 459 1,635 1,404 — 2,201 Total Assets 16,665 15,892 16,500 4,012 53,068 Capital expenditures 915 298 319 — 1,532 Non-current assets 4,096 4,448 2,427 — 10,971 Goodwill 645 450 1,317 — 2,412 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2018 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 5,494 7,069 12,505 — 25,070 Sales of RPPs & leases 3,750 1,254 82 — 5,086 Sales of spare parts and services 1,780 6,157 1,070 — 9,007 Total sales 11,025 14,480 13,657 — 39,163 External other revenues 19 — — — 19 Total revenues 11,044 14,480 13,657 — 39,183 Total COS (5,312) (8,178) (8,775) — (22,266) Gross profit 5,732 6,302 4,882 — 16,917 R&D expenses (2,394) (1,410) (285) — (4,088) Selling and marketing expenses (4,628) (2,357) (3,566) — (10,551) G&A expenses (1,036) (731) (580) (1,247) (3,593) Total expenses (8,057) (4,498) (4,431) (1,247) (18,232) Operating income (loss) from operations (2,325) 1,804 451 (1,247) (1,316) Total Assets 13,648 16,700 13,149 5,243 48,740 Capital expenditures 1,154 451 324 — 1,928 Non-current assets 2,855 3,697 1,462 — 8,013 Goodwill 645 403 1,364 — 2,412 ​

VALUATION ACCOUNTS

VALUATION ACCOUNTS	12 Months Ended
	Dec. 31, 2020
VALUATION ACCOUNTS
VALUATION ACCOUNTS	30— VALUATION ACCOUNTS ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance Allowance ​ ​ ​ ​ for deferred ​ for doubtful ​ Slow-moving ​ Warranty ​ ​ tax assets ​ accounts ​ inventory ​ reserve Balance as of December 31, 2017 14,266 1,029 723 449 Charges to costs and expenses 515 365 355 433 Deductions: write-off and others (228) 10 (104) (334) Balance as of December 31, 2018 14,553 1,404 974 548 Charges to costs and expenses 859 94 333 131 Deductions: write-off and others (435) (9) (223) (308) Balance as of December 31, 2019 14,977 1,490 1,085 370 Charges to costs and expenses 596 90 651 266 Deductions: write-off and others (65) (858) (172) (268) Balance as of December 31, 2020 15,508 722 1,563 368 ​

SUPPLEMENTAL DISCLOSURES OF CAS

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION	12 Months Ended
	Dec. 31, 2020
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION	31— SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION Interest and income taxes paid are as follows: ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Income taxes paid (refunds received) 377 289 407 Interest paid 124 87 49 Interest received 10 17 12 ​ ​ ​ ​ ​ ​ ​ ​ Non-cash transactions: 2020 2019 2018 Financing lease obligations incurred 192 203 427 Operating lease obligations incurred 317 3,483 — ​ Cash paid for amounts included in the measurement of lease liabilities: ​ ​ ​ ​ ​ 2020 Operating cash flow used in operating leases 941 Operating cash flow used in finance leases 18 Financing cash flow used in finance leases 321 ​

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	12 Months Ended
	Dec. 31, 2020
RELATED PARTY TRANSACTIONS
RELATED PARTY TRANSACTIONS	32— RELATED PARTY TRANSACTIONS On August On March On August On April On September

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Dec. 31, 2020
SUBSEQUENT EVENTS
SUBSEQUENT EVENTS	33— SUBSEQUENT EVENTS N/A

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	12 Months Ended
	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Nature of operations	1-1 EDAP TMS S.A. and its subsidiaries (‘‘the Company’’) are engaged in the development, production, marketing, distribution and maintenance of a portfolio of minimally-invasive medical devices for the treatment of urological diseases. The Company currently produces innovative robotic devices for treating stones of the urinary tract and localized prostate cancer. We also derive revenues from the distribution of urodynamics products and urology lasers. Net sales consist primarily of direct sales to hospitals and clinics in France and Europe, export sales to third-party distributors and agents, and export sales through subsidiaries based in Germany, Italy, the United States and Asia. The Company purchases the majority of the components used in its products from a number of suppliers but for some components, relies on a single source. Delay would be caused if the supply of these components or other components was interrupted and these delays could be extended in certain situations where a component substitution may require regulatory approval. Failure to obtain adequate supplies of these components in a timely manner could have a material adverse effect on the Company’s business, financial position and results of operations. Since the occurrence in 2020 of the COVID-19 virus, we have taken steps to require the majority of our employees to work remotely, maintain minimum supply chain and development activity and curtail most business travels. The pandemic has resulted in further postponement and/or cancelation of the sale and installation of new devices and disposables in hospitals or clinics as investment decisions are put on hold or their resources are refocused on COVID-19. During this period, we benefited from covid related assistance loans from French, Japanese and US authorities.
Basis of preparation	1-2 These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (U.S. GAAP).
Management estimates	1-3 The preparation of financial statements in conformity with U.S. generally accepted accounting principles (‘‘U.S. GAAP’’) requires management to make estimates and assumptions, such as business plans, stock price volatility, duration of standard warranty per market, duration and interest rate of operating leases, price of maintenance contract used to determine the amount of revenue to be deferred and life duration of our range of products. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. In particular regarding the estimate of future sales in our business plans, the prolonged impact of the COVID19 pandemic and lack of visibility on the return to normal sales cycles has created a higher level of uncertainty. Actual results could differ from those estimates.
Consolidation	1-4 The accompanying consolidated financial statements include the accounts of EDAP TMS S.A. and all its domestic and foreign owned subsidiaries after elimination of intercompany balances and transactions. We do not have any significant interests in any variable interest entities.
Revenue recognition	1-5 The Company adopted ASC Topic 606, Revenue from Contracts with Customers The Company’s revenue consists of: - Sales of goods (devices and consumables), where invoicing generally takes place upon delivery. Consumables revenues included in sales contract are deferred until delivery. - Revenue-per-Procedures (“RPP”) and leases: they comprise (i) - Sales of spare parts and services (maintenance, upgrades, mobility and others). Spare parts are invoiced when delivered. Regarding services, invoicing is performed either on a subscription basis (in advance or at the end of the period) or when performed. Sales of our medical devices and sales of disposables, sales of RPPs and leases, and sales of spare parts and services, are all net of commissions. The Company invoices its customers based on the billing schedules in its sales arrangements. Payments are generally due between one to three The Company accounts for a contract with a customer when there is a legally enforceable contract between the Company and its customer, the rights of the goods or services and their payment terms can be identified, the contract has commercial substance, collectability of the contract consideration is probable, it is approved and the parties are committed to their obligations. Our sale arrangements may contain multiple elements, including device(s), consumables and services. For these multiple-element arrangements, the Company accounts for individual goods and services as separate performance obligations: (i) For multiple-element arrangements, revenue is allocated to each performance obligation based on its relative standalone selling price. Standalone selling prices are based on observable prices at which the Company separately sells the goods or services. If a standalone selling price is not directly observable, then the Company estimates the standalone selling price considering market conditions and entity-specific factors including, but not limited to, features and functionality of the goods and services, geographies, and type of customer. The Company regularly reviews standalone selling prices and updates these estimates as necessary. The Company recognizes revenue when the performance obligations are satisfied by transferring control over the goods or service to a customer. The Company’s revenue consists of the following: Sales of goods: Sales of goods are and have historically been comprised of sales net of commission of medical devices (ESWL lithotripters and HIFU devices) and net sales of disposables (mostly Ablapaks and Focalpaks in the HIFU division and electrodes in the ESWL division). Sales of goods also includes products such as urology laser and urodynamics devices distributed through our agents and third-party distributors. For devices and disposables, revenue is recognized when the Company transfers control to the customer (i.e. when the customer has the ability to direct the use of, and obtain substantially all of the remaining benefit from, the device or disposables), which is generally at the point of delivery or installation, depending on the terms of the arrangement (i.e. when the customer can use the goods to provide services or sell or exchange the good), and based on contractual incoterms. Such installation-related costs are immaterial in the context of the contract with the customer and do not constitute a distinct performance obligation. The Company’s sales arrangements do not provide a right of return. The goods are generally covered by a period of one to two Sales of RPPs and leases: Sales of RPP and leases include the revenues from the sale of treatment procedures and from the leasing of machines. For RPP, we provide machines to clinics and hospitals for free for a limited period, rather than selling the devices. These hospitals and clinics perform treatments using the devices and usually pay us based on the number of individual treatments provided. Revenues from leasing of machine are considered as immaterial. Revenues related to the sale of treatments invoiced on a ‘‘Revenue-Per-Procedure’’ (‘‘RPP’’) basis are recognized when the treatment procedure has been completed. Revenues from devices leased to customers under operating leases are recognized on a straight-line basis. Regarding multiple-element arrangements with a lease component, a portion of the contract is allocated to the lease component on the basis of observable market prices applied by the Company for similar devices under operating leases. The lease component is recognized on a straight line basis over the contractual period. Other immaterial components under the contract are recognized in accordance with their nature. Sales of spare parts and services: Revenues related to spare parts are recognized when spare parts are delivered to distributors who perform their own maintenance services. Spare parts used in the performance of EDAP’s own maintenance and repair services are generally not recognized separately, unless a type of spare part is specifically excluded from the maintenance contract terms. Revenues related to Services mainly consist of maintenance contracts which rarely exceed one The Company recognizes revenue for extended warranties included in the multiple-element arrangements as a separate performance obligation in Sales of services on a straight-line basis over the extended warranty period. In the majority of countries in which the Company operates, the statutory warranty period is one to two Agents and distributors: As part of its sale process in countries other than continental France, when the Company does not have a local subsidiary, sales of goods to end-customers are performed through agents and distributors. Such agents and distributors are primarily responsible for the sales’ process, bear the inventory risk, and are free to determine the sale prices. Sales of goods to agents and distributors are recognized when the control is transferred to the related agent or distributor which generally occurs based on contractual incoterms. Deferred revenue: Deferred revenue for the periods presented primarily relates to service contracts where the service fees are billed up-front, generally quarterly or annually, prior to those services having been performed, and consists primarily of billing or cash receipts in advance of services due under maintenance contracts or extended warranty contracts. The associated deferred revenue is generally recognized ratably over the service period. Disaggregation of revenue: Disaggregation by primary geographical market, and timing of revenue recognition is reported in Note Contract Balances: Details on contract liabilities are reported on Note The Company applies the practical expedient in paragraph 606-10-50-14 and does not disclose information about remaining performance obligations that have original expected durations of one
Costs of sales	1-6 Costs of sales include all direct product costs, costs related to shipping, handling, duties and importation fees, as well as certain indirect costs such as service and supply chain departments expenses. Indirect costs are allocated by type of sales (goods, RPP and leases, spare parts and services) using an allocation method determined by management by type of costs and segment activities and reviewed on an annual basis.
Shipping and handling costs	1-7 Shipping and handling costs are not considered as performance obligations. Shipping and handling costs are recorded as a component of cost of sales.
Cash equivalents and short term investments	1-8 Cash equivalents are cash investments which are highly liquid and have initial maturities of 90 Cash investments with a maturity higher than 90
Accounts Receivable	1-9 The Company maintains an allowance for doubtful accounts for estimated losses inherent in its accounts receivable portfolio. In establishing the required allowance, management considers historical losses adjusted to take into account current market conditions and the Company’s customers’ financial condition, the amount of receivables in dispute, and the current receivables aging and current payment patterns. The Company reviews its allowance for doubtful accounts
Inventories	1-10 Inventories are valued at the lower of cost and net realizable value. Cost is either the manufacturing cost, which is principally comprised of components and labor costs for our own manufactured products, or purchase price for urology products we distribute. Cost is determined on a first-in, first-out basis for components and spare parts and by specific identification for finished goods (medical devices). The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow moving, first based on a detailed comparison between quantity in inventory and historical consumption and then based on case-by-case analysis of the difference between the cost of inventory and the related estimated market value.
Property and equipment	1-11 Property and equipment is stated at historical cost, net of accumulated depreciation and impairment. Depreciation of property and equipment is calculated using the straight-line method over the estimated useful life of the related assets, as follows: ​ ​ ​ ​ ​ ​ ​ ​ Leasehold improvements (in years) ​ ​ 10 or lease term if shorter ​ ​ Equipment (in years) 3 — 10 Furniture, fixtures, fittings and other (in years) 2 ​ — 10 ​ Equipment includes industrial equipment and research equipment that has alternative future uses. Equipment also includes devices that are manufactured by the Company and leased to customers through operating leases related to Revenue-Per-Procedure transactions and devices subject to sale and leaseback transactions. This equipment is depreciated over a period of seven years.
Long-lived assets	1-12 The Company reviews the carrying value of its long-lived assets, including fixed assets and intangible assets, for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be fully recoverable. Recoverability of long-lived assets is assessed by a comparison of the carrying amount of the assets (or the Group of assets, including the asset in question, that represents the lowest level of separately-identifiable cash flows) to the total estimated undiscounted cash flows expected to be generated by the asset or group of assets. If the future net undiscounted cash flows is less than the carrying amount of the asset or group of assets, the asset or group of assets is considered impaired and an expense is recognized equal to the amount required to reduce the carrying amount of the asset or group of assets to its then fair value. Fair value is determined by discounting the cash flows expected to be generated by the assets, when the quoted market prices are not available for the long-lived assets. Estimated future cash flows are based on assumptions and are subject to risk and uncertainty.
Goodwill and intangible assets	1-13 Goodwill represents the excess of purchase price over the fair value of identifiable net assets of businesses acquired. Goodwill is not amortized but instead tested annually for impairment or more frequently when events or change in circumstances indicate that the assets might be impaired. When imparement indicators are identified, the impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, including goodwill. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. For the purpose of any impairment test, the Company relies upon projections of future undiscounted cash flows and takes into account assumptions regarding the evolution of the market and its ability to successfully develop and commercialize its products. Changes in market conditions could have a major impact on the valuation of these assets and could result in additional impairment losses. Intangible assets consist primarily of purchased patents relating to lithotripters, purchased licenses, a purchased trade name and a purchased trademark. The basis for valuation of these assets is their historical acquisition cost. Amortization of intangible assets is calculated by the straight-line method over the shorter of the contractual or estimated useful life of the assets, as follows: ​ ​ ​ ​ Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7 ​
Treasury Stocks	1-14 Treasury stock purchases are accounted for at cost. The sale of treasury stocks is accounted for using the first in first out method. Gains on the sale or retirement of treasury stocks are accounted for as additional paid-in capital whereas losses on the sale or retirement of treasury stock are recorded as additional paid-in capital to the extent that previous net gains from sale or retirement of treasury stocks are included therein; otherwise the losses shall be recorded to accumulated benefit (deficit) account. Gains or losses from the sale or retirement of treasury stock do not affect reported results of operations. Treasury stocks held by a Company cannot exceed 10% of the total number of shares issued.
Warranty expenses	1-15 The Company provides customers with a warranty for each product sold and accrues warranty expense at time of sale based upon historical claims experience. Standard warranty period may vary from 1
Income taxes	1-16 The Company accounts for income taxes in accordance with ASC 740, ‘‘Accounting for Income Taxes’’ Under ASC 740, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax basis of assets and liabilities and are measured by applying enacted tax rates and laws to taxable Under ASC740, the measurement of a tax position that meets the more-likely-that-not recognition threshold must take into consideration the amounts and probabilities of the outcomes that could be realized upon ultimate settlement using the facts, circumstances and information available at the reporting date.
Research and development costs	1-17 Research and development costs are recorded as an expense in the period in which they are incurred. The French government provides tax credits to companies for innovative research and development. This tax credit is calculated based on a
Advertising costs	1-18 Advertising costs are recorded as an expense in the period in which they are incurred and are included in selling and administrative expenses in the accompanying consolidated statements of income (loss). Advertising costs amounted to €291 thousand, €739 thousand and €719 thousand for the
Foreign currency translation and transactions	1-19 Translation of the financial statements of consolidated companies The reporting currency of EDAP TMS S.A. for all ● assets and liabilities are translated at year-end exchange rates; ● shareholders’ equity is translated at historical exchange rates (as of the date of contribution); ● statement of income (loss) items are translated at average exchange rates for the year; and ● translation gains and losses are recorded in a separate component of shareholders’ equity. Foreign currencies transactions Transactions involving foreign currencies are translated into the functional currency using the exchange rate prevailing at the time of the transactions. Receivables and payables denominated in foreign currencies are translated at Presentation in the Statement of Income (loss) Aggregate foreign currency transactions gains and losses are disclosed in a single caption in the Statement of Income (loss) under section “Foreign currency exchange gain (loss), net”.
Earnings per share	1-20 Basic earnings per share is computed by dividing income available to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted earnings per share reflects potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the earnings of the Company. The dilutive effects of the Company’s common stock options and warrants is determined using the treasury stock method to measure the number of shares that are assumed to have been repurchased using the average market price during the period, which is converted from U.S. dollars at the average exchange rate for the period.
Derivative instruments	1-21 ASC 815 requires the Company to recognize all of its derivative instruments as either assets or liabilities in the statement of financial position at fair value. The accounting for changes in the fair value (i.e., gains or losses) of a derivative instrument depends on whether it has been designated and qualifies as part of a hedging relationship and further, on the type of hedging relationship. For those derivative instruments that are designated and qualify as hedging instruments, the Company must classify the hedging instrument, based upon the exposure being hedged, as fair value hedge, cash flow hedge or a hedge of a net investment in a foreign operation. Gains and losses from derivative instruments are recorded in the Statement of Income (loss). As of December
Employee stock option plans	1-22 At December
Warrants	1-23 The Company recorded outstanding warrants issued in March 2012, May 2013 and April 2016 as a liability. Pursuant to guidance of ASC 815-40-15-7(i), the Company determined that the said warrants could not be considered as being indexed to the Company’s own stock, on the basis that the exercise price of the warrants was determined in U.S. dollars while the functional currency of the Company is the Euro. Since December 31, 2018, there were no more warrants outstanding.
Leases	1-24 Leases as a Lessee In accordance with ASC 842, Leases, and as from January controls Leases are classified as either finance leases or operating leases. Substantially all our operating leases are comprised of office space leases, and substantially all our finance leases are comprised of office furniture and technology equipment. The Company recognizes a right-of-use (“ROU”) asset and a lease liability at the lease commencement date. The right-of-use asset is initially measured at cost, which primarily comprises the initial amount of the lease liability, plus any initial direct costs incurred, plus prepaid lease payments, less any lease incentives received. All ROU assets are reviewed for impairment. For operating leases, the lease liability is initially measured at the present value of the unpaid lease payments at lease commencement date, discounted using the incremental borrowing rate for assets of same duration or characteristics. For finance leases the lease liability is initially measured in the same manner and date as for operating leases and is subsequently measured at amortized cost using the effective interest method For operating leases, the ROU asset is subsequently measured throughout the lease term at the carrying amount of the lease liability, plus initial direct costs, plus (minus) any prepaid (accrued) lease payments, less the unamortized balance of lease incentives received. Lease expense for lease payments is recognized on a straight-line basis over the lease term. For finance leases, the ROU asset is subsequently amortized using the straight-line method from the lease commencement date to the earlier of the end of its useful life or the end of the lease term unless the lease transfers ownership of the underlying asset to the Company or the Company is reasonably certain to exercise an option to purchase the underlying asset. In those cases, the ROU asset is amortized over the useful life of the underlying asset. Amortization of the ROU asset is recognized and presented separately from interest expense on the lease liability. Lease payments included in the measurement of the lease liability comprise the following: the fixed payments, including in-substance fixed payments over the lease term (which includes termination penalties the Company would owe if the lease term assumes the Company’s exercise of a termination option), variable lease payments that depend on an index or ratepayments for optional renewal periods where it is reasonably certain the renewal period will be exercised, the exercise price of an option to purchase the underlying asset if the company is reasonably certain to exercise the option, and amounts expected to be paymable under a Company provided residual value guarantee. Documentation of the discount rates used is provided by a credit simulation carried out by the bank for similar goods and duration. Variable lease payments associated with the Company’s leases are recognized when the event, activity, or circumstance in the lease agreement on which those payments are assessed occurs. Variable lease payments are presented as operating expenses in the Company’s consolidated statements of income in the same line item as expenses arising from fixed lease payments (operating leases) or amortization of the ROU asset (finance leases). Our real estate leases generally include non-lease maintenance services. The consideration in the contract is allocated to the lease and non-lease components based on standalone selling prices. Some of our real estate leases contain variable lease payments, including payments based on an index or rate. Variable lease payments based on an index or rate are initially measured using the index or rate in effect at lease commencement, and changes to index and rate-based variable lease payments are recognized in profit or loss in the period of the change. Variable payments that do not depend on an index or rate, such as rental payments based on the use of the underlying asset or property taxes and insurance reimbursement, are recorded as operating expense when incurred. Lease modifications result in remeasurement of the lease payments when that modification is not accounted for as a separate contract. Lease expense for operating leases consists of the lease payments plus any initial direct costs, primarily brokerage commissions, and is recognized on a straight-line basis over the lease term. Included in lease expense are any variable lease payments incurred in the period that were not included in the initial lease liability. Lease expense for finance leases consists of the amortization of the right-of-use asset on a straight-line basis over the lease term and interest expense determined on an amortized cost basis. The lease payments are allocated between a reduction of the lease liability and interest expense. The lease term for all of the Company’s leases includes the non-cancellable period of the lease plus any additional periods covered by either a Company option to extend (or not to terminate) the lease that the Company is reasonably certain to exercise, or an option to extend (or not to terminate) the lease controlled by the lessor . We have elected not to recognize right-of-use assets and lease liabilities for short-term leases that have a term of 12 Leases as a Lessor: A lessor shall classify a lease as a sales-type lease when the lease meets any of the following criteria at lease commencement: ● The lease transfers ownership of the underlying asset to the lessee by the end of the lease term. ● The lease grants the lessee an option to purchase the underlying asset that the lessee is reasonably certain to exercise. ● The lease term is for the major part of the remaining economic life of the underlying asset. However, if the commencement date falls at or near the end of the economic life of the underlying asset, this criterion shall not be used for purposes of classifying the lease. ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments in accordance with paragraph 842-10-30-5(f) equals or exceeds substantially all of the fair value of the underlying asset. ● The underlying asset is of such a specialized nature that it is expected to have no alternative use to the lessor at the end of the lease term. When none of the criteria are met: A lessor shall classify the lease as either a direct financing lease or an operating lease. A lessor shall classify the lease as an operating lease unless both of the following criteria are met, in which case the lessor shall classify the lease as a direct financing lease: ● The present value of the sum of the lease payments and any residual value guaranteed by the lessee that is not already reflected in the lease payments in accordance with paragraph 842-10-30-5(f) and/or any other third party unrelated to the lessor equals or exceeds substantially all of the fair value of the underlying asset; ● It is probable that the lessor will collect the lease payments plus any amount necessary to satisfy a residual value guarantee.
Recent accounting pronouncements	1-25 Recently Adopted Accounting Pronouncements In February 2016, the FASB issued ASU No. 2016-02, Leases (ASU 2016-02), which supersedes ASC 840 “Leases” and creates a new topic, ASC 842 "Leases." This update requires lessees to recognize on their balance sheet a lease liability and a lease asset for all leases, including operating leases, with a term greater than 12 months. The update also expands the required quantitative and qualitative disclosures surrounding leases. This update is effective for fiscal years beginning after December 15, 2018 and interim periods within those fiscal years, with earlier application permitted. The Company adopted the new standard as of January 1, 2019. The Company performed an analysis of all contracts to identify lease components or rights of use. The Company determined that the new standard mostly applies to leases for facilities situated in France, Japan and in the U.S. and for Company’s equipment, vehicles and IT equipment. The last category has been determined as being below the threshold and not material. The Company adopted ASC 842 using a modified retrospective transition approach for all leases existing at or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company adopted the new standard as of January 1, 2019 with practical expedients, and did not restate comparative prior periods. The adoption of ASC 842 had a material effect on our consolidated balance sheet, but did not materially affect the consolidated statement of income (loss). The most significant impact was the recognition of the operating lease right-of-use assets and the liability for operating leases. The accounting for finance leases (capital leases) was substantially unchanged. Accordingly, upon adoption, leases that were classified as operating leases under ASC 840 were classified as operating leases under ASC 842, and we recorded an adjustment of €3.5 million to operating lease right-of-use assets and the related lease liability in 2019 In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses: Measurement of Credit Losses on Financial Instruments, or ASU 2016-13, which changes the impairment model for most financial assets. This standard has been amended with codification improvements in ASU 2018-19, 2019-04, 2019-05, 2019-11. The new model uses a forward-looking expected loss method, which generally results in earlier recognition of allowances for losses. ASU 2016-13 was effective for annual and interim periods beginning after December 15, 2019 and early adoption was permitted for annual and interim periods beginning after December 15, 2018. The Company adopted ASU 2016-13 on January 1, 2020. The application of ASU 2016-3 did not have a significant impact on our accounts. In January 2017, the FASB issued ASU 2017-04, “Intangibles - Goodwill and Other: Simplifying the Test for Goodwill Impairment.” This update eliminates step 2 from the goodwill impairment test, and requires the goodwill impairment test to be performed by comparing the fair value of a reporting unit with its carrying amount. An impairment charge should be recognized for the amount by which the carrying amount exceeds the reporting unit’s fair value; however, the loss recognized should not exceed the total amount of goodwill allocated to that reporting unit. This guidance was effective for the Company in the first quarter of 2020. Early adoption was permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The application of ASU 2016-3 did not have a significant impact on our accounts.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Dec. 31, 2020
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Schedule of depreciation of property and equipment is estimated useful life of the related assets	​ ​ ​ ​ ​ ​ ​ ​ Leasehold improvements (in years) ​ ​ 10 or lease term if shorter ​ ​ Equipment (in years) 3 — 10 Furniture, fixtures, fittings and other (in years) 2 ​ — 10
Schedule of amortization of intangible assets is contractual or estimated useful life of the assets	​ ​ ​ ​ Patents (in years) 5 SAP Licenses (in years) 10 Other licenses (in years) 5 Trade name and trademark (in years) 7

TRADE ACCOUNTS AND NOTES RECE_2

TRADE ACCOUNTS AND NOTES RECEIVABLE, NET (Tables)	12 Months Ended
	Dec. 31, 2020
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET
Schedule of trade accounts and notes receivable	​ ​ ​ ​ ​ ​ ​ 2020 2019 Trade accounts receivable 11,363 11,807 Notes receivable 667 1,013 Less: allowance for doubtful accounts (722) (1,490) Total 11,307 11,330 Less current portion (11,307) (11,328) Total long-term portion — 2

OTHER RECEIVABLES (Tables)

OTHER RECEIVABLES (Tables)	12 Months Ended
	Dec. 31, 2020
OTHER RECEIVABLES
Schedule of other receivables	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2020 2019 Research and development tax credit receivable from the French State ​ 492 766 Value-added taxes receivable ​ 403 422 Other receivables from Government and public authorities ​ 64 26 Others ​ 72 46 Total ​ 1,031 1,259

INVENTORIES (Tables)

INVENTORIES (Tables)	12 Months Ended
	Dec. 31, 2020
INVENTORIES
Schedule of Inventory, Current	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2020 2019 Components, spare parts ​ 6,050 4,959 Work-in-progress ​ 226 584 Finished goods – own manufactured products ​ 1,283 1,737 Finished goods – distribution products ​ 1,994 1,981 Total gross inventories ​ 9,552 9,262 Less: allowance for slow-moving inventory and net realizable value ​ (1,563) (1,085) Total ​ 7,989 8,178

OTHER ASSETS (Tables)

OTHER ASSETS (Tables)	12 Months Ended
	Dec. 31, 2020
OTHER ASSETS
Schedule of other assets	​ ​ ​ ​ ​ ​ ​ ​ December 31, ​ 2020 2019 Prepaid expenses, current portion ​ 369 447 Total ​ 369 447

PROPERTY AND EQUIPMENT, NET (Ta

PROPERTY AND EQUIPMENT, NET (Tables)	12 Months Ended
	Dec. 31, 2020
PROPERTY AND EQUIPMENT, NET
Schedule of Property and equipment	​ ​ ​ ​ ​ ​ ​ 2020 2019 Equipment ​ 8,405 ​ 7,002 Furniture, fixture, and fittings and other 2,736 2,776 Total gross value 11,141 9,778 Less: accumulated depreciation and amortization (8,142) (6,644) Total 3,000 3,134
Schedule of Finance lease right-of-use assets	​ ​ ​ ​ ​ ​ ​ 2020 2019 Equipment 359 713 Vehicles and IT equipment 1,196 1,582 Total gross value 1,554 2,295 Less: accumulated depreciation and amortization 850 1,360 Total 704 935

OPERATING LEASE RIGHT-OF-USE _2

OPERATING LEASE RIGHT-OF-USE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2020
OPERATING LEASE RIGHT-OF-USE ASSETS
Schedule of Operating lease right-of-use assets	​ ​ ​ ​ ​ ​ ​ 2020 2019 Facilities 1,584 2,387 Equipment 237 58 Furniture, fixture, and fittings and other 74 202 Total net operating lease right of use 1,895 2,647

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	12 Months Ended
	Dec. 31, 2020
GOODWILL AND INTANGIBLE ASSETS
Schedule of Intangible assets	​ ​ ​ ​ ​ ​ ​ 2020 2019 Licenses 1,570 1,466 Trade name and trademark 412 427 Patents 412 412 Organization costs 225 320 Total gross value 2,619 2,625 Accumulated amortization for licenses (813) (699) Accumulated amortization for trade name and trademark (409) (424) Accumulated amortization for patents (412) (412) Accumulated amortization for organization costs (225) (320) Less: Total accumulated amortization (1,858) (1,855) Total 761 770
Schedule of Intangible assets, annual estimated amortization expense	​ ​ ​ ​ ​ December 31, ​ 2020 2021 113 2022 106 2023 94 2024 87 2025 87 Total 488

TRADE ACCOUNTS AND NOTES PAYA_2

TRADE ACCOUNTS AND NOTES PAYABLE (Tables)	12 Months Ended
	Dec. 31, 2020
TRADE ACCOUNTS AND NOTES PAYABLE
Schedule of Accounts Payable and Accrued Liabilities	​ ​ ​ ​ ​ ​ ​ 2020 2019 Trade accounts payable 5,708 6,034 Notes payable — 12 Total 5,708 6,046

DEFERRED REVENUES (Tables)

DEFERRED REVENUES (Tables)	12 Months Ended
	Dec. 31, 2020
DEFERRED REVENUES
Schedule of Deferred revenues	​ ​ ​ ​ ​ ​ ​ 2020 2019 Deferred revenues on maintenance contracts ​ 1,761 ​ 1,741 Deferred revenue on RPP ​ 255 ​ 243 Deferred revenue on sale of devices ​ 135 ​ 115 Deferred revenue on extension of warranty, included in sales contracts ​ 782 ​ 837 Deferred research and development grants ​ 693 ​ 269 Total ​ 3,627 ​ 3,205 Less long term portion ​ (926) ​ (1,313) Current portion ​ 2,701 ​ 1,892
Schedule of Deferred revenue on extension of warranty	​ ​ ​ ​ ​ December 31, ​ 2020 2021 300 2022 314 2023 143 2024 18 2025 8 Total 782
Components of deferred revenue on extension of warranty	​ ​ ​ ​ ​ Total Balance as of December 31, 2018 855 New extension of warranty 254 Recognition of revenue (272) Balance as of December 31, 2019 837 New extension of warranty 206 Recognition of revenue (261) Balance as of December 31, 2020 782

OTHER ACCRUED LIABILITIES (Tabl

OTHER ACCRUED LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2020
OTHER ACCRUED LIABILITIES
Schedule of Other Accrued Liabilities	​ ​ ​ ​ ​ ​ ​ 2020 2019 Retirement indemnities 2,665 2,444 Provision for warranty costs 368 370 Accruals for payroll and associated taxes 734 738 Conditional government advances 1,097 1,071 Value added tax payable 420 557 Advances received from customers 551 — Provision for Asset Retirement Obligation (Japan) 113 117 Provision for employee termination indemnities (Korea) 69 56 Others 477 323 Total 6,494 5,676 Less non-current portion (3,720) (3,567) Current portion 2,774 2,109
Schedule of Conditional Advances	​ ​ ​ ​ 2021 6 2022 214 2023 214 2024 214 2025 and thereafter 447 Total 1,097
Schedule of Changes is the Provision for Warranty Costs	​ ​ ​ ​ ​ ​ ​ 2020 2019 Beginning of year 370 547 Amount used during the year (268) (308) New warranty expenses 266 131 End of year 368 370 Less current portion (262) (260) Long term portion 106 110

LEASE OBLIGATIONS (Tables)

LEASE OBLIGATIONS (Tables)	12 Months Ended
	Dec. 31, 2020
LEASE OBLIGATIONS
Schedule of Maturities of Finance Leases Liabilities	​ ​ ​ ​ ​ December 31, ​ 2020 2021 360 2022 280 2023 190 2024 72 2025 and thereafter 28 Total undiscounted minimum lease payments 930 Less: amount representing interest (33) Present value of minimum lease payments 899 Less: current portion (344) Long-term portion 555
Schedule of Maturities of Operating Leases Liabilities	​ ​ ​ ​ ​ December 31, ​ 2020 2021 803 2022 523 2023 381 2024 195 2025 and thereafter — Total undiscounted minimum lease payments 1,901 Less: current portion (802) Long-term portion 1,099

LONG TERM DEBT AND FINANCIAL _2

LONG TERM DEBT AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE (Tables)	12 Months Ended
	Dec. 31, 2020
LONG TERM DEBT AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE
Schedule of Long-term Debt	​ ​ ​ ​ ​ ​ ​ December 31, ​ 2020 2019 France term loan 4,394 351 Japanese term loan (YEN) 900 617 Germany term loan 193 438 USA term loan 180 — Malaysia term loan 8 13 Total long term debt 5,675 1,420 Less current portion (4,532) (462) Total long-term portion 1,143 957
Schedule of Long-term Debt Instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP Technomed Co. Ltd 80,000,000 ​ August 2, 2026 1.98 % Monthly instalment EDAP Technomed Co. Ltd 50,000,000 ​ April 2, 2025 1.8 % Monthly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP Technomed Co. Ltd 80,000,000 ​ August 2, 2026 1.98 % Monthly instalment EDAP Technomed Co. Ltd 40,000,000 ​ April 15, 2020 2.91 % Monthly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS GMBH 400,000 ​ April 30, 2023 2.40 % Monthly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS GMBH 136,500 ​ December 31, 2022 2.25 % Monthly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS GMBH 450,000 ​ November 30, 2020 2.49 % Monthly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 700,000 ​ October 16, 2021 0.40 % Quarterly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 218,000 ​ April 1, 2025 0.99 % Monthly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ August 11, 2021 0.25 % Monthly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 2,000,000 ​ August 4, 2021 0.25 % Monthly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TMS FRANCE 700,000 ​ October 16, 2021 0.40 % Quarterly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TECHNOMED SDN BHD 90,000 ​ July 31, 2022 4.64 % Monthly instalment ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Initial ​ ​ Frequency of ​ Amount ​ Maturity ​ Fixed Interest rate principal payments EDAP TECHNOMED INC 221,217 ​ May 14, 2022 1 % Monthly instalment
Schedule of Long-term Debt and Financial Instrument Maturities	​ ​ ​ ​ 2021 4,532 2022 504 2023 228 2024 200 2025 and thereafter 210 Total 5,675

OTHER LONG-TERM LIABILITIES (Ta

OTHER LONG-TERM LIABILITIES (Tables)	12 Months Ended
	Dec. 31, 2020
OTHER LONG-TERM LIABILITIES
Schedule of Other Long-term Liabilities	​ ​ ​ ​ ​ ​ ​ 2020 2019 Provision for retirement indemnities (Japan & France), less current portion 2,273 2,167 Provision for employee termination indemnities (Korea) less current portion 69 56 Provision for Asset Retirement Obligation (Japan) less current portion 113 117 Provision for warranty costs, less current portion 106 110 Conditional government advances, less current portion 1,097 1,071 Accrued interest less current portion 62 46 Total 3,720 3,567 ​
Defined Benefit Plan, Assumptions	​ ​ ​ ​ ​ ​ ​ ​ Pension benefits France ​ ​ 2020 ​ 2019 Discount rate 0.60 % 0.90 % Salary increase 2.50 % 2.50 % Retirement age 65 65 ​ Average retirement remaining service period 24 24 ​ ​ ​ ​ ​ ​ ​ ​ ​ Pension benefits Japan ​ ​ 2020 ​ 2019 Discount rate 0.60 % 0.60 % Salary increase 2.50 % 2.50 % Retirement age 60 60 ​ Average retirement remaining service period 14 14 ​ ​
Schedule of Amounts Recognized in Balance Sheet	In 2020, provision presentation according to ASC 715 in thousands of euros ​ ​ ​ ​ ​ ​ ​ France Japan Non-current liabilities ​ 1,032 ​ 1,241 Current liabilities 80 69 Accumulated other comprehensive income (loss) (111) (130) Total 1,000 1,181 ​ In 2019, provision presentation according to ASC 715 in thousands of euros: ​ ​ ​ ​ ​ ​ ​ France Japan Non-current liabilities ​ 960 ​ 1,207 Current liabilities 10 22 Accumulated other comprehensive income (loss) (67) (136) Total 903 1,093 ​
Schedule of Defined Benefit Plans Disclosures	​ ​ ​ ​ ​ ​ ​ ​ France 2020 2019 2018 Change in benefit obligations: Benefit obligations at beginning of year 969 976 895 Service cost 88 68 67 Interest cost 9 16 14 Net loss or (gain) — 2 — Actuarial (gain) or loss 45 (93) ​ ​ Amortization of net prior service cost 1 1 1 Benefits paid — — — Benefit obligations at end of year (1) 1,111 969 976 Unrecognized actuarial (gain) loss (2) 94 48 141 Unrecognized prior service cost (2) 17 18 20 Accrued pension cost 1,000 903 815 (1) The accumulated benefit obligation was €800 thousand and €693 thousand at December 31, 2020 and 2019 respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2020 is €1 thousand. ​ ​ ​ ​ ​ ​ ​ ​ Japan 2020 2019 2018 Change in benefit obligations: Benefit obligations at beginning of year 1,230 1,311 1,182 Service cost 123 140 131 Interest cost 7 6 6 Amortization of net loss 1 27 26 Actuarial (gain) / loss (1) (294) — Benefits paid (5) (3) (94) Exchange rate impact (44) 42 (60) Benefit obligations at end of year (1) 1,310 1,230 1,311 Unrecognized actuarial (gain) loss (2) 130 136 416 Unrecognized prior service cost (2) — — — Accrued pension cost 1,181 1,093 895 (1) The accumulated benefit obligation was €1,134 thousand and €1,062 thousand at December 31, 2020 and 2019, respectively. (2) The amount in accumulated other comprehensive income (loss) to be recognized as components of net periodic benefit costs in 2020 is €1 thousand.
Schedule of Expected Benefit Payments	​ ​ ​ ​ ​ ​ ​ France Japan 2021 80 70 2022 — 105 2023 67 114 2024 — 157 2025 — 167 2026-2030 318 397 ​ 465 1,008

SHAREHOLDERS' EQUITY (Tables)

SHAREHOLDERS' EQUITY (Tables)	12 Months Ended
	Dec. 31, 2020
SHAREHOLDERS' EQUITY
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Weighted-average expected life (years) — (2) 6.25 6.25 ​ Expected volatility rates (1) — 49.45 % 52.6 % Expected dividend yield — 0 % 0 % Risk-free interest rate — (0.08) % 0.18 % Weighted-average exercise price (€) — 3.90 2.65 ​ Weighted-average fair value of options granted during the year (€) — 1.93 1.33 ​ (1) Historical volatility calculated over 10 years. ​ (2) There was no new plan for the year 2020. ​
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 ​ 2018 ​ ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ ​ average ​ ​ ​ average ​ ​ ​ ​ exercice ​ ​ ​ exercice ​ ​ ​ exercice ​ Options price (€) Options price (€) Options price (€) Outstanding on January 1, 1,273,900 2.78 1,347,600 2.61 1,207,600 2.61 Granted — — 155,000 3.90 165,000 2.65 Exercised (23,750) 2.54 (143,700) 2.16 — — Forfeited (21,250) 2.55 (85,000) 1.94 (25,000) 3.05 Expired (42,000) 2.38 — — — — Outstanding on December 31, 1,186,900 2.81 1,273,900 2.78 1,347,600 2.61 Exercisable on December 31, 970,650 2.73 818,900 2.60 772,600 2.44 Share purchase options available for grant on December 31, 292,428 ​ 250,428 250,428 ​
Share-based Payment Arrangement, Option, Exercise Price Range	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Outstanding options ​ Fully vested options (1) ​ ​ ​ ​ Weighted ​ Weighted ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ average ​ average ​ Aggregate ​ ​ ​ average ​ Aggregate ​ ​ ​ ​ remaining ​ exercise ​ Intrinsic ​ ​ ​ exercise ​ Intrinsic ​ ​ ​ ​ contractual ​ price ​ Value ​ ​ ​ price ​ Value Exercise price (€) Options life (€) (2) Options (€) (2) 3.90 130,000 8.8 3.90 42,576 32,500 3.90 13,017 3.22 465,000 5.3 3.22 468,492 465,000 3.22 468,492 2.65 145,000 7.7 2.65 228,739 72,500 2.65 114,369 2.39 184,400 6.3 2.39 338,837 138,150 2.39 253,852 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ 1.91 262,500 2.0 1.91 608,346 262,500 1.91 608,346 1.91 to 3.90 1,186,900 6.0 2.81 1,686,989 970,650 2.73 1,458,076 (1) Fully vested options are all exercisable options. (2) The aggregate intrinsic value represents the total pre-tax intrinsic value, based on the Company’s closing stock price of $5.17 at December 31, 2020, which would have been received by the option holders had all in-the-money option holders exercised their options as of that date.
Schedule of Nonvested Share Activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average ​ ​ ​ ​ Grant-Date Fair ​ Options Value (€) Non-vested at January 1, 2018 ​ 593,750 ​ 1.53 Granted ​ 165,000 ​ 1.33 Vested ​ (180,000) ​ 1.56 Forfeited ​ (3,750) ​ 1.29 Non-vested at December 31, 2018 ​ 575,000 ​ 1.47 Non-vested at January 1, 2019 ​ 575,000 ​ 1.47 Granted ​ 155,000 ​ 1.93 Vested ​ (204,000) ​ 1.52 Forfeited ​ (70,600) ​ 1.58 Non-vested at December 31, 2019 ​ 455,000 ​ 1.58 Non-vested at January 1, 2020 455,000 1.58 Granted 0 0 Vested (235,000) 1.58 Forfeited (3,750) 1.54 Non-vested at December 31, 2020 216,250 1.59 ​
Schedule of Accumulated Other Comprehensive Income (Loss)	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2020 ​ ​ Foreign currency ​ ​ ​ ​ ​ ​ translation ​ Provision for ​ ​ ​ ​ adjustment ​ retirement indemnities ​ Total Beginning balance (3,234) (203) (3,436) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) 410 (38) 372 Ending balance (2,824) (241) (3,064) ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Year Ended December 31, 2019 ​ ​ Foreign currency ​ ​ ​ ​ ​ ​ translation ​ Provision for ​ ​ ​ ​ adjustment ​ retirement indemnities ​ Total Beginning balance (3,173) (577) (3,748) Other comprehensive income (loss) before reclassifications — — — Reclassified from accumulated other comprehensive loss — — — Net current-period other comprehensive income (loss) (61) 374 313 Ending balance (3,234) (203) (3,436) ​

TOTAL SALES (Tables)

TOTAL SALES (Tables)	12 Months Ended
	Dec. 31, 2020
TOTAL SALES
Disaggregation of Revenue	​ ​ ​ ​ ​ ​ ​ ​ Timing of revenue recognition 2020 2019 2018 Products transferred at a point in time 32,862 36,767 31,373 Products and services transferred over time 8,787 8,092 7,790 ​ 41,649 44,859 39,163
Revenue from External Customers by Geographic Areas	​ ​ ​ ​ ​ ​ ​ ​ Primary geographical markets (€) 2020 2019 2018 Asia 15,872 17,939 14,119 France 10,021 11,350 11,577 United States 5,611 5,194 2,048 Others geographical areas 10,146 10,377 11,419 ​ 41,649 44,859 39,163 ​

OTHER REVENUES (Tables)

OTHER REVENUES (Tables)	12 Months Ended
	Dec. 31, 2020
OTHER REVENUES
Schedule of Other Revenues	​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Licenses and others 12 52 19 Total 12 52 19 ​

COSTS OF SALES (Tables)

COSTS OF SALES (Tables)	12 Months Ended
	Dec. 31, 2020
COSTS OF SALES
Schedule of Costs of Sales	​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Direct costs of sales (14,058) (14,919) (13,683) Indirect costs of sales (9,225) (8,990) (8,583) Total costs of sales (23,283) (23,909) (22,266)

RESEARCH AND DEVELOPMENT EXPE_2

RESEARCH AND DEVELOPMENT EXPENSES (Tables)	12 Months Ended
	Dec. 31, 2020
RESEARCH AND DEVELOPMENT EXPENSES
Schedule of Research and Development Expenses	​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Gross research and development expenses (5,173) (4,727) (4,863) Research Tax Credit 492 762 685 Grants 184 236 90 Net Research and development expenses (4,496) (3,728) (4,088)

FINANCIAL INCOME, NET (Tables)

FINANCIAL INCOME, NET (Tables)	12 Months Ended
	Dec. 31, 2020
FINANCIAL INCOME, NET
Schedule of Interest Income and Interest Expense	​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Interest income ​ 10 ​ 20 ​ 19 Interest expense (108) (165) (111) Warrants exercised / forfeited — — 889 Total (98) (146) 797 ​ ​ ​ ​ ​ ​ ​

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Dec. 31, 2020
INCOME TAXES
Schedule of Income before Income Tax, Domestic and Foreign	​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 France ​ (2,042) ​ 1,803 ​ 1,687 Other countries 854 388 (1,667) Total (1,188) 2,191 20
Schedule of Components of Income Tax Expense (Benefit)	​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Current income tax expense: ​ ​ ​ France (158) (237) (163) Other countries (312) (550) (351) Sub-total current income tax expense (471) (787) (515) Deferred income tax (expense) benefit: France 8 (1) 2 Other countries (53) 109 155 Sub-total deferred income tax (expense) benefit (45) 108 157 Total (516) (679) (358)
Schedule of Deferred Tax Assets and Liabilities	​ ​ ​ ​ ​ ​ ​ 2020 2019 Net operating loss carry forwards ​ 14,014 ​ 13,642 Elimination of intercompany profit in inventory 161 269 Elimination of intercompany profit in fixed assets 244 349 Provisions for retirement indemnities 634 577 Capital leases treated as operating leases for tax 56 29 Other items 775 544 Total deferred tax assets 15,883 15,410 Total deferred tax liabilities — — Net deferred tax assets 15,883 15,410 Valuation allowance for deferred tax assets (15,508) (14,977) Deferred tax assets (liabilities), net of allowance 374 432 ​
Schedule of Effective Income Tax Rate Reconciliation	​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Theoretical tax income / (loss) at French statutory tax rate ​ 333 ​ (614) ​ (6) Income of foreign subsidiaries taxed at different tax rates 9 (51) (124) Effect of net operating loss carry-forwards and valuation allowances (858) 189 (210) Non-taxable debt fair value variation — — 235 Permanent differences (159) (251) (392) Effect of cancellation of intra-group positions 152 (54) 35 French business tax included in income tax (CVAE) (156) (159) (161) Other 164 263 265 Effective income (loss) tax (516) (679) (358) ​

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	12 Months Ended
	Dec. 31, 2020
EARNINGS (LOSS) PER SHARE
Schedule of Earnings Per Share, Basic and Diluted	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ December 31, 2020 December 31, 2019 December 31, 2018 Income (loss) available to common shareholders (in Euros) ​ € (1,703,668) ​ € 1,512,056 ​ € (338,382) Number of shares for the computation of basic EPS ​ 29,148,108 ​ 29,016,118 ​ 28,997,866 Basic EPS (in Euros) ​ € (0.06) ​ € 0.05 ​ € (0.01) Effect of dilutive securities ​ 622,723 ​ 604,238 ​ 347,500 Number of shares for the computation of diluted EPS ​ 29,148,108 ​ 29,615,466 ​ 28,997,866 Diluted EPS income / (loss) (in Euros) ​ € (0.06) ​ € 0.05 ​ € (0.01) ​

FAIR VALUE OF FINANCIAL INSTR_2

FAIR VALUE OF FINANCIAL INSTRUMENTS (Tables)	12 Months Ended
	Dec. 31, 2020
FAIR VALUE OF FINANCIAL INSTRUMENTS
Schedule of fair value measurement inputs level 1	​ ​ ​ ​ ​ ​ ​ ​ ​ ASC 820 December December ​ ​ Level ​ 31, 2020 ​ 31, 2019 Assets: ​ ​ ​ Cash and cash equivalents Level 1 24,696 20,886 Liabilities: Short-term borrowings Level 1 2,638 3,513 Long-Term Debt Level 1 5,675 1,420

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2020
SEGMENT INFORMATION
Schedule of Reconciliation of Operating Profit (Loss) from Segments to Consolidated	​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Segment operating income (loss) 269 2,201 (1,315) Financial income (expense), net (98) (146) 797 Foreign Currency exchange (losses) gains, net (1,359) 136 538 Income tax (expense) credit (516) (679) (358) Consolidated net profit (loss) (1,704) 1,512 (338)
Schedule of Segment Reporting Information, by Segment	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2020 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 6,000 6,248 15,274 ​ ​ 27,523 Sales of RPPs & leases 3,594 927 224 ​ ​ 4,745 Sales of spare parts and services 1,831 5,707 1,844 ​ ​ 9,382 Total sales 11,425 12,882 17,342 ​ ​ 41,649 External other revenues 12 — — ​ ​ 12 Total revenues 11,438 12,882 17,342 ​ ​ 41,662 Total COS (5,144) (7,232) (10,906) ​ ​ (23,283) Gross profit 6,293 5,649 6,436 ​ ​ 18,379 R&D expenses (2,583) (1,555) (358) ​ ​ (4,496) Selling and marketing expenses (3,151) (2,052) (4,076) ​ ​ (9,279) G&A expenses (1,005) (964) (900) (1,465) (4,335) Total expenses (6,738) (4,572) (5,335) (1,465) (18,110) Operating income (loss) from operations (445) 1,078 1,102 (1,465) 269 Total Assets 16,279 15,567 20,795 2,551 55,193 Capital expenditures 1,144 309 557 — 2,011 Non-current assets 3,706 2,466 3,628 — 9,801 Goodwill 645 496 1,271 — 2,412 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2019 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 8,311 6,715 15,084 — 30,111 Sales of RPPs & leases 4,162 1,426 158 — 5,747 Sales of spare parts and services 1,618 6,048 1,335 — 9,001 Total sales 14,092 14,190 16,578 — 44,859 External other revenues 52 — — — 52 Total revenues 14,144 14,190 16,578 — 44,912 Total COS (6,152) (7,816) (9,941) — (23,909) Gross profit 7,991 6,374 6,637 — 21,002 R&D expenses (1,962) (1,394) (372) — (3,728) Selling and marketing expenses (4,402) (2,441) (4,008) — (10,850) G&A expenses (1,168) (904) (854) — (4,224) Total expenses (7,533) (4,738) (5,233) — (18,802) Operating income (loss) from operations 459 1,635 1,404 — 2,201 Total Assets 16,665 15,892 16,500 4,012 53,068 Capital expenditures 915 298 319 — 1,532 Non-current assets 4,096 4,448 2,427 — 10,971 Goodwill 645 450 1,317 — 2,412 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ HIFU ESWL DISTRIB Reconciling Total 2018 ​ Division ​ Division ​ Division ​ Items ​ consolidated Sales of goods 5,494 7,069 12,505 — 25,070 Sales of RPPs & leases 3,750 1,254 82 — 5,086 Sales of spare parts and services 1,780 6,157 1,070 — 9,007 Total sales 11,025 14,480 13,657 — 39,163 External other revenues 19 — — — 19 Total revenues 11,044 14,480 13,657 — 39,183 Total COS (5,312) (8,178) (8,775) — (22,266) Gross profit 5,732 6,302 4,882 — 16,917 R&D expenses (2,394) (1,410) (285) — (4,088) Selling and marketing expenses (4,628) (2,357) (3,566) — (10,551) G&A expenses (1,036) (731) (580) (1,247) (3,593) Total expenses (8,057) (4,498) (4,431) (1,247) (18,232) Operating income (loss) from operations (2,325) 1,804 451 (1,247) (1,316) Total Assets 13,648 16,700 13,149 5,243 48,740 Capital expenditures 1,154 451 324 — 1,928 Non-current assets 2,855 3,697 1,462 — 8,013 Goodwill 645 403 1,364 — 2,412

VALUATION ACCOUNTS (Tables)

VALUATION ACCOUNTS (Tables)	12 Months Ended
	Dec. 31, 2020
VALUATION ACCOUNTS
Schedule of valuation accounts	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Allowance Allowance ​ ​ ​ ​ for deferred ​ for doubtful ​ Slow-moving ​ Warranty ​ ​ tax assets ​ accounts ​ inventory ​ reserve Balance as of December 31, 2017 14,266 1,029 723 449 Charges to costs and expenses 515 365 355 433 Deductions: write-off and others (228) 10 (104) (334) Balance as of December 31, 2018 14,553 1,404 974 548 Charges to costs and expenses 859 94 333 131 Deductions: write-off and others (435) (9) (223) (308) Balance as of December 31, 2019 14,977 1,490 1,085 370 Charges to costs and expenses 596 90 651 266 Deductions: write-off and others (65) (858) (172) (268) Balance as of December 31, 2020 15,508 722 1,563 368

SUPPLEMENTAL DISCLOSURES OF C_2

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION (Tables)	12 Months Ended
	Dec. 31, 2020
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Schedule of interest and income taxes paid	​ ​ ​ ​ ​ ​ ​ ​ ​ 2020 2019 2018 Income taxes paid (refunds received) 377 289 407 Interest paid 124 87 49 Interest received 10 17 12 ​ ​ ​ ​ ​ ​ ​ ​ Non-cash transactions: 2020 2019 2018 Financing lease obligations incurred 192 203 427 Operating lease obligations incurred 317 3,483 — ​ ​ ​ ​ ​ 2020 Operating cash flow used in operating leases 941 Operating cash flow used in finance leases 18 Financing cash flow used in finance leases 321

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Jan. 01, 2019
Warranty term	one to two years
Short term investments	€ 0
Accounts Receivable, Allowance for Credit Loss, Writeoff	827	€ 15
Gain (loss) derivatives	0
Warranty expense	266	131	€ 433
Advertising Expense	291	739	€ 719
Operating lease, right of use	€ 1,895	2,647
Operating lease, liability		€ 2,684
Accounting Standards Update 2016-02
Operating lease, right of use				€ 3,500
Operating lease, liability				€ 3,500
Maximum | Sale and leaseback
Useful life	7 years

SUMMARY OF SIGNIFICANT ACCOUN_5

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and equipment (Details)	12 Months Ended
	Dec. 31, 2020
Leasehold improvements
Property and equipment
Useful life	10 years
Equipment | Minimum
Property and equipment
Useful life	3 years
Equipment | Maximum
Property and equipment
Useful life	10 years
Furniture, fixtures, fittings and other | Minimum
Property and equipment
Useful life	2 years
Furniture, fixtures, fittings and other | Maximum
Property and equipment
Useful life	10 years

SUMMARY OF SIGNIFICANT ACCOUN_6

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Intangible Assets (Details)	12 Months Ended
	Dec. 31, 2020
Patents
Intangible assets
Useful life (in years)	5 years
SAP Licenses
Intangible assets
Useful life (in years)	10 years
Other licenses
Intangible assets
Useful life (in years)	5 years
Trade name and trademark
Intangible assets
Useful life (in years)	7 years

TRADE ACCOUNTS AND NOTES RECE_3

TRADE ACCOUNTS AND NOTES RECEIVABLE, NET (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
TRADE ACCOUNTS AND NOTES RECEIVABLE, NET
Trade accounts receivable	€ 11,363	€ 11,807
Notes receivable	667	1,013
Less: allowance for doubtful accounts	(722)	(1,490)
Total	11,307	11,330
Less current portion	(11,307)	(11,328)
Total long-term portion		2
Bad debt expense:
Bad debt expense	€ 87	€ 84	€ 362

OTHER RECEIVABLES - (Details)

OTHER RECEIVABLES - (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
OTHER RECEIVABLES
Research and development tax credit receivable from the French State	€ 492	€ 766
Value-added taxes receivable	403	422
Other receivables from Government and public authorities	64	26
Others	72	46
Other receivables	€ 1,031	€ 1,259

INVENTORIES (Details)

INVENTORIES (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
INVENTORIES
Components, spare parts	€ 6,050	€ 4,959
Work-in-progress	226	584
Finished goods - own manufactured products	1,283	1,737
Finished goods - distribution products	1,994	1,981
Total gross inventories	9,552	9,262
Less: allowance for slow-moving inventory and net realizable value	(1,563)	(1,085)
Total	7,989	8,178
Provision for slow moving inventory:
Inventory Write-down	€ 651	€ 168	€ 227

OTHER ASSETS (Details)

OTHER ASSETS (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
OTHER ASSETS
Prepaid expenses, current portion	€ 369	€ 447
Other assets, current portion	€ 369	€ 447

PROPERTY AND EQUIPMENT, NET (De

PROPERTY AND EQUIPMENT, NET (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Property and equipment
Depreciation expense	€ 1,695	€ 1,511	€ 981
Capitalized costs on equipment leased to customers	11,141	9,778
Accumulated amortization	8,142	6,644
Depreciation expense related to financing lease right-of-use assets	401	448	386
Reduction to Right-of-use Assets Resulting From Reduction to Financing Lease Liability	670	122
Assets leased to customers
Property and equipment
Depreciation expense	240	23	€ 51
Capitalized costs on equipment leased to customers	264	342
Accumulated amortization	€ 102	€ 95

PROPERTY AND EQUIPMENT, NET - S

PROPERTY AND EQUIPMENT, NET - Schedule of Property and Equipment,net (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property and equipment
Property and equipment, gross	€ 11,141	€ 9,778
Less: accumulated depreciation and amortization	(8,142)	(6,644)
Property and equipment, net	3,000	3,134
Equipment
Property and equipment
Property and equipment, gross	8,405	7,002
Furniture, fixture, and fittings and other
Property and equipment
Property and equipment, gross	€ 2,736	€ 2,776

PROPERTY AND EQUIPMENT, NET -_2

PROPERTY AND EQUIPMENT, NET - Schedule of Financing leases right-of-use assets (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Property and equipment
Finance Lease, Right-of-Use Asset, before Accumulated Amortization	€ 1,554	€ 2,295
Less: accumulated depreciation and amortization	(850)	(1,360)
Total	704	935
Equipment
Property and equipment
Finance Lease, Right-of-Use Asset, before Accumulated Amortization	359	713
Vehicles and IT equipment
Property and equipment
Finance Lease, Right-of-Use Asset, before Accumulated Amortization	€ 1,196	€ 1,582

OPERATING LEASE RIGHT-OF-USE _3

OPERATING LEASE RIGHT-OF-USE ASSETS (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
OPERATING LEASE RIGHT-OF-USE ASSETS
Reduction to Right-of-use Assets Resulting From Reduction to Operating Lease Liability	€ 931	€ 836
Variable Lease, Cost	101	108
Short-term Lease, Cost	€ 71	€ 71

OPERATING LEASE RIGHT-OF-USE _4

OPERATING LEASE RIGHT-OF-USE ASSETS (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Right of use assets:
Operating lease, right of use	€ 1,895	€ 2,647
Facilities
Right of use assets:
Operating lease, right of use	1,584	2,387
Equipment
Right of use assets:
Operating lease, right of use	237	58
Furniture, fixture, fittings and other
Right of use assets:
Operating lease, right of use	€ 74	€ 202

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS (Details) € in Thousands	12 Months Ended
	Dec. 31, 2020EUR (€)item	Dec. 31, 2019EUR (€)	Dec. 31, 2018EUR (€)
Goodwill
Goodwill	€ 2,412	€ 2,412
Reporting units | item	3
Impairment	€ 0
Amortization expense	113	€ 113	€ 110
Urology Devices and Services (ESWL)
Goodwill
Goodwill	496
Distribution Services (DIST)
Goodwill
Goodwill	1,271
High Intensity Focused Ultrasound (HIFU)
Goodwill
Goodwill	€ 645

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Intangible assets
Intangible assets, gross	€ 2,619	€ 2,625
Accumulated amortization	(1,858)	(1,855)
Intangible assets, net	761	770
Licenses
Intangible assets
Intangible assets, gross	1,570	1,466
Accumulated amortization	(813)	(699)
Trade name and trademark
Intangible assets
Intangible assets, gross	412	427
Accumulated amortization	(409)	(424)
Patents
Intangible assets
Intangible assets, gross	412	412
Accumulated amortization	(412)	(412)
Organization Costs
Intangible assets
Intangible assets, gross	225	320
Accumulated amortization	€ (225)	€ (320)

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Estimated amortization expense (Details) € in Thousands	Dec. 31, 2020EUR (€)
GOODWILL AND INTANGIBLE ASSETS
2021	€ 113
2022	106
2023	94
2024	87
2025	87
Total	€ 488

TRADE ACCOUNTS AND NOTES PAYA_3

TRADE ACCOUNTS AND NOTES PAYABLE (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
TRADE ACCOUNTS AND NOTES PAYABLE
Trade accounts payable	€ 5,708	€ 6,034
Notes payable		12
Trade accounts and notes payable	€ 5,708	€ 6,046

DEFERRED REVENUES - Summary of

DEFERRED REVENUES - Summary of Deferred Revenues (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Deferred revenues, total	€ 3,627	€ 3,205
Less long term portion	(926)	(1,313)
Deferred revenues, current portion	2,701	1,892
Maintenance [Member]
Deferred revenues, total	1,761	1,741
RPP [Member]
Deferred revenues, total	255	243
Sale of Devices [Member]
Deferred revenues, total	135	115
Extension of Warranty [Member]
Deferred revenues, total	782	837	€ 855
Research and Development Grants [Member]
Deferred revenues, total	€ 693	€ 269

DEFERRED REVENUES - Recognition

DEFERRED REVENUES - Recognition Period (Details) € in Thousands	Dec. 31, 2020EUR (€)
Extension of Warranty [Member]
Revenue, remaining performance obligation, amount	€ 782

DEFERRED REVENUES - Deferred Re

DEFERRED REVENUES - Deferred Revenue Recognition Period 2 (Details) - Extension of Warranty [Member] € in Thousands	Dec. 31, 2020EUR (€)
Revenue, remaining performance obligation, amount	€ 782
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2021-01-01
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year)	1 year
Revenue, remaining performance obligation, amount	€ 300
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2022-01-01
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year)	1 year
Revenue, remaining performance obligation, amount	€ 314
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-01-01
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year)	1 year
Revenue, remaining performance obligation, amount	€ 143
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year)	1 year
Revenue, remaining performance obligation, amount	€ 18
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, remaining performance obligation, expected timing of satisfaction, period (Year)	1 year
Revenue, remaining performance obligation, amount	€ 8

DEFERRED REVENUES - Change in D

DEFERRED REVENUES - Change in Deferred Revenue on Extension of Warranty (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance	€ 3,205
Balance	3,627	€ 3,205
Extension of Warranty [Member]
Balance	837	855
New extension of warranty	206	254
Recognition of revenue	(261)	(272)
Balance	€ 782	€ 837

OTHER ACCRUED LIABILITIES (Deta

OTHER ACCRUED LIABILITIES (Details)	Dec. 31, 2020
OTHER ACCRUED LIABILITIES
Conditional Advances, Interest Rate, Percentage	1.44%

OTHER ACCRUED LIABILITIES - Sch

OTHER ACCRUED LIABILITIES - Schedule of Other Accrued Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Retirement indemnities	€ 2,665	€ 2,444
Provision for warranty costs	368	370	€ 547
Accruals for payroll and associated taxes	734	738
Conditional government advances	1,097	1,071
Value added tax payable	420	557
Advances received from customers	551
Provision for Asset Retirement Obligation (Japan)	113	117
Others	477	323
Total	6,494	5,676
Less non-current portion	(3,720)	(3,567)
Current portion	2,774	2,109
KOREA, REPUBLIC OF
Provision for employee termination indemnities	€ 69	€ 56

OTHER ACCRUED LIABILITIES - Con

OTHER ACCRUED LIABILITIES - Conditional Advances (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
OTHER ACCRUED LIABILITIES
2021	€ 6
2022	214
2023	214
2024	214
2025 and thereafter	447
Total	€ 1,097	€ 1,071

OTHER ACCRUED LIABILITIES - S_2

OTHER ACCRUED LIABILITIES - Schedule of Changes in Warranty Costs Provision (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
OTHER ACCRUED LIABILITIES
Beginning of year	€ 370	€ 547
Amount used during the year	(268)	(308)
New warranty expenses	266	131
End of year	368	370
Less current portion	(262)	(260)
Long term portion	€ 106	€ 110

LEASE OBLIGATIONS (Details)

LEASE OBLIGATIONS (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Finance Lease, Liability, Total	€ 899	€ 1,044
Finance Lease, Interest Expense	€ 33	€ 29
Finance Lease, Weighted Average Remaining Lease Term (Year)	2 years 4 months 17 days	3 years 2 months 12 days
Finance Lease, Weighted Average Discount Rate, Percent	3.06%	2.44%
Operating Lease, Weighted Average Remaining Lease Term (Year)	2 years 9 months 18 days	3 years 6 months 3 days
Operating Lease, Weighted Average Discount Rate, Percent	1.45%	1.56%
Operating Lease, Expense	€ 941	€ 828	€ 1,002
Medical Devices [Member]
Finance Lease, Liability, Total	223
Vehicles and Other IT Equipment [Member]
Finance Lease, Liability, Total	€ 676

LEASE OBLIGATIONS - Maturities

LEASE OBLIGATIONS - Maturities of Finance Leases Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
LEASE OBLIGATIONS
2020		€ 415
2021	€ 360	299
2022	280	221
2023	190	122
2024	72
2024 and thereafter		30
2025 and thereafter	28
Total undiscounted minimum lease payments	930	1,086
Less: amount representing interest	(33)	(41)
Present value of minimum lease payments	899	1,044
Less: current portion	(344)	(392)
Long-term portion	€ 555	€ 653

LEASE OBLIGATIONS - Maturitie_2

LEASE OBLIGATIONS - Maturities of Operating Leases Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
LEASE OBLIGATIONS
2020		€ 980
2021	€ 803	758
2022	523	474
2023	381	349
2024	195
2024 and thereafter		171
Total undiscounted minimum lease payments	1,901	2,732
Less: amount representing interest		(48)
Present value of minimum lease payments		2,684
Less: current portion	(802)	(958)
Long-term portion	€ 1,099	€ 1,726

SHORT-TERM BORROWINGS (Details)

SHORT-TERM BORROWINGS (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Short-term borrowings	€ 2,638	€ 3,513
Factored Account Receivables [Member]
Short-term borrowings	€ 2,638	3,185
Short Borrowing Japan [Member]
Short-term borrowings		€ 328

LONG TERM DEBT AND FINANCIAL _3

LONG TERM DEBT AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE (Details) - Loans Payable [Member]	Dec. 31, 2020EUR (€)	Nov. 30, 2020EUR (€)	Oct. 31, 2020EUR (€)	Apr. 30, 2020JPY (¥)	Dec. 31, 2019EUR (€)
Debt Instrument, Face Amount	€ 6,000,000
JAPAN
Debt Instrument, Collateral Amount | ¥				¥ 40,000,000
GERMANY | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member]
Debt Instrument, Collateral Amount		€ 450,000
GERMANY | Urology Devices and Services (UDS) Equipment [Member]
Debt Instrument, Collateral Amount					€ 136,000
GERMANY | High Intensity Focused Ultrasound (HIFU) Equipment 2 [Member]
Debt Instrument, Collateral Amount	438,000
France | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member]
Debt Instrument, Collateral Amount	€ 1,530,000		€ 218,000

LONG TERM DEBT AND FINANCIAL _4

LONG TERM DEBT AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE - Schedule of Long Term Debt (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Long term debt	€ 5,675	€ 1,420
Less current portion	(4,532)	(462)
Long-term debt, non-current	1,143	957
France
Long term debt	4,394	351
JAPAN
Long term debt	900	617
GERMANY
Long term debt	193	438
USA
Long term debt	180
Malaysia
Long term debt	€ 8	€ 13

LONG TERM DEBT AND FINANCIAL _5

LONG TERM DEBT AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE - Long-term Debt (Details) $ in Thousands	1 Months Ended			12 Months Ended
	Dec. 31, 2020JPY (¥)	Nov. 30, 2020EUR (€)	Oct. 31, 2020EUR (€)	Dec. 31, 2020JPY (¥)	Dec. 31, 2019JPY (¥)	Dec. 31, 2020EUR (€)	Dec. 31, 2020USD ($)	Dec. 31, 2019EUR (€)
JAPAN | EDAP Technomed Co Ltd. [Member] | Loan One [Member]
Debt Instrument, Face Amount | ¥	¥ 80,000,000			¥ 80,000,000	¥ 80,000,000
Maturity				Aug. 2, 2026	Aug. 2, 2026
Interest rate	1.98%			1.98%	1.98%	1.98%	1.98%	1.98%
Frequency of principal payments				Monthly instalment	Monthly instalment
JAPAN | EDAP Technomed Co Ltd. [Member] | Loan Two [Member]
Debt Instrument, Face Amount | ¥	¥ 50,000,000			¥ 50,000,000	¥ 40,000,000
Maturity				Apr. 2, 2025	Apr. 15, 2020
Interest rate	1.80%			1.80%	2.91%	1.80%	1.80%	2.91%
Frequency of principal payments				Monthly instalment	Monthly instalment
GERMANY | EDAP TMS GMBH [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member] | Loan One [Member]
Debt Instrument, Face Amount		€ 450,000				€ 400,000		€ 136,500
Maturity		Nov. 30, 2020		Apr. 30, 2023	Dec. 31, 2022
Interest rate	2.40%	2.49%		2.40%	2.25%	2.40%	2.40%	2.25%
Frequency of principal payments		Monthly instalment		Monthly instalment	Monthly instalment
France | EDAP TMS France [Member] | Loan One [Member]
Debt Instrument, Face Amount			€ 218,000			€ 700,000		€ 700,000
Maturity			Apr. 1, 2025	Oct. 16, 2021	Oct. 16, 2021
Interest rate	0.40%		0.99%	0.40%	0.40%	0.40%	0.40%	0.40%
Frequency of principal payments			Monthly instalment	Quarterly instalment	Quarterly instalment
France | EDAP TMS France [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 1 [Member] | Loan One [Member]
Debt Instrument, Face Amount						€ 2,000,000
Maturity	Aug. 11, 2021
Interest rate	0.25%			0.25%		0.25%	0.25%
Frequency of principal payments	Monthly instalment
France | EDAP TMS France [Member] | High Intensity Focused Ultrasound (HIFU) Equipment 2 [Member] | Loan One [Member]
Debt Instrument, Face Amount						€ 2,000,000
Maturity	Aug. 4, 2021
Interest rate	0.25%			0.25%		0.25%	0.25%
Frequency of principal payments	Monthly instalment
Malaysia | EDAP Technomed Sdn Bdh [Member]
Debt Instrument, Face Amount | $							$ 90
Maturity				Jul. 31, 2022
Interest rate	4.64%			4.64%		4.64%	4.64%
Frequency of principal payments				Monthly instalment
USA | EDAP Technomed Co Ltd. [Member]
Debt Instrument, Face Amount						€ 221,217
Maturity				May 14, 2022
Interest rate	1.00%			1.00%		1.00%	1.00%
Frequency of principal payments				Monthly instalment

LONG TERM DEBT AND FINANCIAL _6

LONG TERM DEBT AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE - Schedule Of Long-term Debt and Financial Instruments Maturities (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
LONG TERM DEBT AND FINANCIAL INSTRUMENTS CARRIED AT FAIR VALUE
2021	€ 4,532
2022	504
2023	228
2024	200
2025 and thereafter	210
Total	€ 5,675	€ 1,420

OTHER LONG-TERM LIABILITIES (De

OTHER LONG-TERM LIABILITIES (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Retirement Indemnity Plans, France [Member]
Defined Benefit Plan, Accumulated Benefit Obligation	€ 800	€ 693
Defined Benefit Plan, Expected Amortization, Next Fiscal Year, Total	1
Defined Benefit Retirement Indemnity Plans, Japan [Member]
Defined Benefit Plan, Accumulated Benefit Obligation	1,134	€ 1,062
Defined Benefit Plan, Expected Amortization, Next Fiscal Year, Total	€ 1

OTHER LONG-TERM LIABILITIES - O

OTHER LONG-TERM LIABILITIES - Other Long-term Liabilities (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019
OTHER LONG-TERM LIABILITIES
Provision for retirement indemnities (Japan & France), less current portion	€ 2,273	€ 2,167
Provision for employee termination indemnities (Korea) less current portion	69	56
Provision for Asset Retirement Obligation (Japan) less current portion	113	117
Provision for warranty costs, less current portion	106	110
Conditional government advances, less current portion	1,097	1,071
Accrued interest less current portion	62	46
Total	€ 3,720	€ 3,567

OTHER LONG-TERM LIABILITIES - A

OTHER LONG-TERM LIABILITIES - Assumptions (Details) - USD ($)	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Retirement Indemnity Plans, France [Member]
Discount rate	0.60%	0.90%
Salary increase	2.50%	2.50%
Retirement age	65	65
Average retirement remaining service period	24	24
Defined Benefit Retirement Indemnity Plans, Japan [Member]
Discount rate	0.60%	0.60%
Salary increase	2.50%	2.50%
Retirement age	60	60
Average retirement remaining service period	14	14

OTHER LONG-TERM LIABILITIES - P

OTHER LONG-TERM LIABILITIES - Provision Presentation According to ASC 715 (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Retirement Indemnity Plans, France [Member]
Non-current liabilities	€ 1,032	€ 960
Current liabilities	80	10
Accumulated other comprehensive income (loss)	(111)	(67)
Accrued pension cost	1,000	903	€ 815
Defined Benefit Retirement Indemnity Plans, Japan [Member]
Non-current liabilities	1,241	1,207
Current liabilities	69	22
Accumulated other comprehensive income (loss)	(130)	(136)
Accrued pension cost	€ 1,181	€ 1,093	€ 895

OTHER LONG-TERM LIABILITIES - R

OTHER LONG-TERM LIABILITIES - Reconciliation of Pension Cost Components (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Defined Benefit Retirement Indemnity Plans, France [Member]
Benefit obligations at beginning of year	€ 969	€ 976	€ 895
Service cost	88	68	67
Interest cost	9	16	14
Net loss or (gain)		2
Actuarial (gain) or loss	45	(93)
Amortization of net prior service cost	1	1	1
Benefit obligations at end of year	1,111	969	976
Unrecognized actuarial (gain) loss	94	48	141
Unrecognized prior service cost	17	18	20
Accrued pension cost	1,000	903	815
Defined Benefit Retirement Indemnity Plans, Japan [Member]
Benefit obligations at beginning of year	1,230	1,311	1,182
Service cost	123	140	131
Interest cost	7	6	6
Amortization of net loss	1	27	26
Actuarial (gain) or loss	(1)	(294)
Benefits paid	(5)	(3)	(94)
Exchange rate impact	(44)	42	(60)
Benefit obligations at end of year	1,310	1,230	1,311
Unrecognized actuarial (gain) loss	130	136	416
Accrued pension cost	€ 1,181	€ 1,093	€ 895

OTHER LONG-TERM LIABILITIES - E

OTHER LONG-TERM LIABILITIES - Expected Benefit Payments (Details) € in Thousands	Dec. 31, 2020EUR (€)
Defined Benefit Retirement Indemnity Plans, France [Member]
2021	€ 80
2023	67
2026-2030	318
Total	465
Defined Benefit Retirement Indemnity Plans, Japan [Member]
2021	70
2022	105
2023	114
2024	157
2025	167
2026-2030	397
Total	€ 1,008

SHAREHOLDERS' EQUITY (Details)

SHAREHOLDERS' EQUITY (Details) - EUR (€) € / shares in Units, € in Thousands	Apr. 26, 2019	Apr. 04, 2019	Aug. 29, 2018	Apr. 25, 2017	Apr. 26, 2016	Jan. 18, 2013	Jul. 31, 2001	Dec. 31, 1998	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2013	Jun. 28, 2019	Feb. 18, 2016	Dec. 31, 2012
Common stock, shares issued									29,457,744	29,433,994
Common stock, par value									€ 0.13	€ 0.13
Commons stock, shares outstanding									29,165,316	29,141,566
Statutory Retained Earnings (Statutory Accumulated Deficit)									€ 16,172
Treasury stock									292,428	292,428
Treasury Stock, Shares, Acquired (in shares)							180,290	112,138
Treasury Stock, Value, Acquired, Par Value Method							€ 928
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)									0	155,000	165,000
Share Price (in EUR per share)									€ 5.17
The 2012 Plan [Member]
Common Stock, Shares Subscribed but Unissued (in shares)																	500,000
The 2016 Plan [Member]
Common Stock, Shares Subscribed but Unissued (in shares)																1,000,000
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share)										€ 3.90	€ 2.65
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)									1,186,900	1,273,900	1,347,600	1,207,600
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)										155,000	165,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)									970,650	818,900	772,600
Stock issued during period shares stock options exercised									23,750	143,700
Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount									€ 105
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)									3 years 3 months
Share-based Payment Arrangement, Option [Member] | The 2012 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)																	500,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share)						€ 1.91
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)						10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)									262,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)						500,000
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture														€ 660
Share-based Payment Arrangement, Option [Member] | The 2012 Plan [Member] | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						1 year
Share-based Payment Arrangement, Option [Member] | The 2012 Plan [Member] | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)						4 years
Share-based Payment Arrangement, Option [Member] | The 2016 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)															1,000,000	1,000,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in EUR per share)		€ 3.90	€ 2.65	€ 2.39	€ 3.22
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)	10 years		10 years	10 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number, Ending Balance (in shares)									924,400
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)		155,000	165,000	260,000	575,000
Shares Granted, Value, Share-based Payment Arrangement, before Forfeiture		€ 299	€ 219									€ 335	€ 960
Share-based Payment Arrangement, Expense									€ 160	€ 260	€ 289
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number (in shares)									708,150
Stock issued during period shares stock options exercised									13,750
Share-based Payment Arrangement, Option [Member] | The 2016 Plan [Member] | Minimum
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	1 year	1 year	1 year	1 year
Share-based Payment Arrangement, Option [Member] | The 2016 Plan [Member] | Maximum
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	4 years	4 years	4 years	4 years
Share-based Payment Arrangement, Option [Member] | The 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)															358,528
Share-based Compensation Arrangement by Share-based Payment Award, Number of pre-existing shares available for future puchase option									292,428
Options to Subscribe New Shares [Member] | The 2019 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)															1,000,000

SHAREHOLDERS' EQUITY - Stock Op

SHAREHOLDERS' EQUITY - Stock Option Assumptions (Details) - € / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
SHAREHOLDERS' EQUITY
Weighted-average expected life (years) (Year)	0 years	6 years 3 months	6 years 3 months
Expected volatility rates(1)		49.45%	52.60%
Expected dividend yield		0.00%	0.00%
Risk-free interest rate			0.18%
Risk-free interest rate		(0.08%)
Weighted-average exercise price () (in EUR per share)		€ 3.90	€ 2.65
Non-vested options granted, weighted average grant-date fair value (in EUR per share)	€ 0	€ 1.93	€ 1.33

SHAREHOLDERS' EQUITY - Disclosu

SHAREHOLDERS' EQUITY - Disclosure of Share-based Compensation Arrangements by Share-based Payment Award (Details) - € / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Non-vested options granted (in shares)	0	155,000	165,000
Share-based Payment Arrangement, Option [Member]
Outstanding - number (in shares)	1,273,900	1,347,600	1,207,600
Outstanding - Weighted average exercise price (in EUR per share)	€ 2.78	€ 2.61	€ 2.61
Non-vested options granted (in shares)		155,000	165,000
Granted - Weighted average exercise price (in EUR per share)		€ 3.90	€ 2.65
Exercised - number (in shares)	(23,750)	(143,700)
Exercised - Weighted average exercise price (in EUR per share)	€ 2.54	€ 2.16
Forfeited - number (in shares)	(21,250)	(85,000)	(25,000)
Forfeited - Weighted average exercise price (in EUR per share)	€ 2.55	€ 1.94	€ 3.05
Expired - number (in shares)	(42,000)
Expired - Weighted average exercise price (in EUR per share)	€ 2.38
Outstanding - number (in shares)	1,186,900	1,273,900	1,347,600
Outstanding - Weighted average exercise price (in EUR per share)	€ 2.81	€ 2.78	€ 2.61
Exercisable - number (in shares)	970,650	818,900	772,600
Exercisable - Weighted average exercise price (in EUR per share)	€ 2.73	€ 2.60	€ 2.44
Share purchase options available for grant - number (in shares)	292,428	250,428	250,428

SHAREHOLDERS' EQUITY - Schedule

SHAREHOLDERS' EQUITY - Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (Details) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2020EUR (€)€ / sharesshares
Outstanding options - Number (in shares) | shares	1,186,900
Outstanding options - Weighted average remaining contractual life (Year)	6 years
Outstanding options - Weighted average exercise price (in EUR per share)	€ 2.81
Outstanding options - Aggregate intrinsic value | €	€ 1,686,989
Exercisable options - Number (in shares) | shares	970,650
Exercisable options - Weighted average exercise price (in EUR per share)	€ 2.73
Exercisable options - Aggregate intrinsic value | €	€ 1,458,076
Exercise price, Lower range (in EUR per share)	€ 1.91
Exercise price, Upper range (in EUR per share)	€ 3.90
Range 1 [Member]
Outstanding options - Number (in shares) | shares	130,000
Outstanding options - Weighted average remaining contractual life (Year)	8 years 9 months 18 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 3.90
Outstanding options - Aggregate intrinsic value | €	€ 42,576
Exercisable options - Number (in shares) | shares	32,500
Exercisable options - Weighted average exercise price (in EUR per share)	€ 3.90
Exercisable options - Aggregate intrinsic value | €	€ 13,017
Exercise price, Lower range (in EUR per share)	€ 3.90
Range 2 [Member]
Outstanding options - Number (in shares) | shares	465,000
Outstanding options - Weighted average remaining contractual life (Year)	5 years 3 months 18 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 3.22
Outstanding options - Aggregate intrinsic value | €	€ 468,492
Exercisable options - Number (in shares) | shares	465,000
Exercisable options - Weighted average exercise price (in EUR per share)	€ 3.22
Exercisable options - Aggregate intrinsic value | €	€ 468,492
Exercise price, Lower range (in EUR per share)	€ 3.22
Range 3 [Member]
Outstanding options - Number (in shares) | shares	145,000
Outstanding options - Weighted average remaining contractual life (Year)	7 years 8 months 12 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 2.65
Outstanding options - Aggregate intrinsic value | €	€ 228,739
Exercisable options - Number (in shares) | shares	72,500
Exercisable options - Weighted average exercise price (in EUR per share)	€ 2.65
Exercisable options - Aggregate intrinsic value | €	€ 114,369
Exercise price, Lower range (in EUR per share)	€ 2.65
Range 4 [member]
Outstanding options - Number (in shares) | shares	184,400
Outstanding options - Weighted average remaining contractual life (Year)	6 years 3 months 18 days
Outstanding options - Weighted average exercise price (in EUR per share)	€ 2.39
Outstanding options - Aggregate intrinsic value | €	€ 338,837
Exercisable options - Number (in shares) | shares	138,150
Exercisable options - Weighted average exercise price (in EUR per share)	€ 2.39
Exercisable options - Aggregate intrinsic value | €	€ 253,852
Exercise price, Lower range (in EUR per share)	€ 2.39
Range 5 [Member]
Outstanding options - Number (in shares) | shares	262,500
Outstanding options - Weighted average remaining contractual life (Year)	2 years
Outstanding options - Weighted average exercise price (in EUR per share)	€ 1.91
Outstanding options - Aggregate intrinsic value | €	€ 608,346
Exercisable options - Number (in shares) | shares	262,500
Exercisable options - Weighted average exercise price (in EUR per share)	€ 1.91
Exercisable options - Aggregate intrinsic value | €	€ 608,346
Exercise price, Lower range (in EUR per share)	€ 1.91

SHAREHOLDERS' EQUITY - Non-vest

SHAREHOLDERS' EQUITY - Non-vested Options Activity (Details) - € / shares	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
SHAREHOLDERS' EQUITY
Non-vested options outstanding (in shares)	455,000	575,000	593,750
Non-vested options outstanding, weighted average grant-date fair value (in EUR per share)	€ 1.58	€ 1.47	€ 1.53
Non-vested options granted (in shares)	0	155,000	165,000
Non-vested options granted, weighted average grant-date fair value (in EUR per share)	€ 0	€ 1.93	€ 1.33
Non-vested options vested (in shares)	(235,000)	(204,000)	(180,000)
Non-vested options vested, weighted average grant-date fair value (in EUR per share)	€ 1.58	€ 1.52	€ 1.56
Non-vested options forfeited (in shares)	(3,750)	(70,600)	(3,750)
Non-vested options forfeited, weighted average grant-date fair value (in EUR per share)	€ 1.54	€ 1.58	€ 1.29
Non-vested options outstanding (in shares)	216,250	455,000	575,000
Non-vested options outstanding, weighted average grant-date fair value (in EUR per share)	€ 1.59	€ 1.58	€ 1.47

SHAREHOLDERS' EQUITY - Componen

SHAREHOLDERS' EQUITY - Components of Accumulated Other Comprehensive Income (Loss) Net of Tax (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Balance	€ 27,359	€ 24,964
Balance	26,248	27,359
Accumulated Foreign Currency Adjustment Attributable to Parent [Member]
Balance	(3,234)	(3,173)
Net current-period other comprehensive income (loss)	410	(61)
Balance	(2,824)	(3,234)
Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member]
Balance	(203)	(577)
Net current-period other comprehensive income (loss)	(38)	374
Balance	(241)	(203)
Other comprehensive income (loss)
Balance	(3,436)	(3,748)
Net current-period other comprehensive income (loss)	372	313
Balance	€ (3,064)	€ (3,436)

TOTAL SALES - Sales by Geograph

TOTAL SALES - Sales by Geographical Area (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues	€ 41,649	€ 44,859	€ 39,163
Asia [Member]
Revenues	15,872	17,939	14,119
France
Revenues	10,021	11,350	11,577
USA
Revenues	5,611	5,194	2,048
Other geographical Areas [Member]
Revenues	€ 10,146	€ 10,377	€ 11,419

TOTAL SALES - Timing of Revenue

TOTAL SALES - Timing of Revenue Recognition (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues	€ 41,649	€ 44,859	€ 39,163
Products transferred at a point in time
Revenues	32,862	36,767	31,373
Products and services transferred over time
Revenues	€ 8,787	€ 8,092	€ 7,790

OTHER REVENUES - Other Revenues

OTHER REVENUES - Other Revenues (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Other revenues:
Revenues	€ 41,649	€ 44,859	€ 39,163
Other revenues
Other revenues:
Revenues	12	52	19
Licenses and others
Other revenues:
Revenues	€ 12	€ 52	€ 19

COSTS OF SALES - Schedule of Co

COSTS OF SALES - Schedule of Costs of Sales (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
COSTS OF SALES
Direct costs of sales	€ (14,058)	€ (14,919)	€ (13,683)
Indirect costs of sales	(9,225)	(8,990)	(8,583)
Total cost of sales	€ (23,283)	€ (23,909)	€ (22,266)

RESEARCH AND DEVELOPMENT EXPE_3

RESEARCH AND DEVELOPMENT EXPENSES - Research and Development Expenses (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
RESEARCH AND DEVELOPMENT EXPENSES
Gross research and development expenses	€ (5,173)	€ (4,727)	€ (4,863)
Research Tax Credit	492	762	685
Grants	184	236	90
Net Research and development expenses	€ (4,496)	€ (3,728)	€ (4,088)

FINANCIAL INCOME, NET - Schedul

FINANCIAL INCOME, NET - Schedule of Financial Income (Expense) (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
FINANCIAL INCOME, NET
Interest income	€ 10	€ 20	€ 19
Interest expense	(108)	(165)	(111)
Warrants exercised / forfeited			889
Financial income (expense), net	€ (98)	€ (146)	€ 797

INCOME TAXES (Details)

INCOME TAXES (Details) € in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2020EUR (€)	Dec. 31, 2018USD ($)	Dec. 31, 2017
Operating Loss Carryforwards, Total		€ 59,052
Deferred Tax Assets, Operating Loss Carryforwards, Foreign		14,014
Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration		€ 57,168
U.S Subsidiary Taxable Net Income Subject to Lower Taxes with New Tax Law, Minimum | $			$ 100
Effective Income Tax Rate Reconciliation, at French Corporate Income Tax Rate, Percent		28.00%
Forecast [Member]
Effective Income Tax Rate Reconciliation, at French Corporate Income Tax Rate, Percent	25.00%
Foreign Tax Authority [Member]
Operating Loss Carryforwards, Total		€ 59,052
Foreign Tax Authority [Member] | Internal Revenue Service (IRS) [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent			21.00%
Foreign Tax Authority [Member] | Minimum | Internal Revenue Service (IRS) [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				15.00%
Foreign Tax Authority [Member] | Maximum | Internal Revenue Service (IRS) [Member]
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent				39.00%
Foreign Tax Authority [Member] | EDAP TMS S.A. [Member]
Operating Loss Carryforwards, Total		34,225
Foreign Tax Authority [Member] | EDAP Technomed Inc. [Member]
Operating Loss Carryforwards, Total		21,134
Foreign Tax Authority [Member] | Edap Technomed Co Ltd Japan [Member]
Operating Loss Carryforwards, Total		1,884
Foreign Tax Authority [Member] | EDAP Technomed Italia S.R.L. [Member]
Operating Loss Carryforwards, Total		1,789
Foreign Tax Authority [Member] | EDAP TMS GMBH [Member]
Operating Loss Carryforwards, Total		€ 20

INCOME TAXES - Income (Loss) Be

INCOME TAXES - Income (Loss) Before Income Taxes (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Income (loss)	€ (1,188)	€ 2,191	€ 20
France
Income (loss)	(2,042)	1,803	1,687
Other countries
Income (loss)	€ 854	€ 388	€ (1,667)

INCOME TAXES - Income Tax Benef

INCOME TAXES - Income Tax Benefit (Expense) (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Current income tax expense	€ (471)	€ (787)	€ (515)
Deferred income tax (expense) benefit	(45)	108	157
Total	(516)	(679)	(358)
France
Current income tax expense	(158)	(237)	(163)
Deferred income tax (expense) benefit	8	(1)	2
Other countries
Current income tax expense	(312)	(550)	(351)
Deferred income tax (expense) benefit	€ (53)	€ 109	€ 155

INCOME TAXES - Deferred Tax Ass

INCOME TAXES - Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2020	Dec. 31, 2019
INCOME TAXES
Net operating loss carry forwards	$ 14,014	$ 13,642
Elimination of intercompany profit in inventory	161	269
Elimination of intercompany profit in fixed assets	244	349
Provisions for retirement indemnities	634	577
Capital leases treated as operating leases for tax, asset	56
Capital leases treated as operating leases for tax, liability		29
Other items	775	544
Total deferred tax assets	15,883	15,410
Net deferred tax assets	15,883	15,410
Valuation allowance for deferred tax assets	(15,508)	(14,977)
Deferred tax assets (liabilities), net of allowance	$ 374	$ 432

INCOME TAXES - Effective Tax Ra

INCOME TAXES - Effective Tax Rate Reconciliation (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
INCOME TAXES
Effective income / (loss) tax at French statutory tax rate	€ 333	€ (614)	€ (6)
Income of foreign subsidiaries taxed at different tax rates	9	(51)	(124)
Effect of net operating loss carry-forwards and valuation allowances	(858)	189	(210)
Non-taxable debt fair value variation			235
Permanent differences	(159)	(251)	(392)
Effect of cancellation of intra-group positions	152	(54)	35
French business tax included in income tax (CVAE)	(156)	(159)	(161)
Other	164	263	265
Effective income (loss) tax	€ (516)	€ (679)	€ (358)

EARNINGS (LOSS) PER SHARE - Sch

EARNINGS (LOSS) PER SHARE - Schedule of Earnings Per Share, Basic and Diluted (Details) - EUR (€) € / shares in Units, € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
EARNINGS (LOSS) PER SHARE
Net income (loss)	€ (1,704)	€ 1,512	€ (338)
Number of shares for the computation of basic EPS (in shares)	29,148,108	29,016,118	28,997,866
Basic EPS (in Euros)	€ (0.06)	€ 0.05	€ (0.01)
Effect of dilutive securities (in shares)	622,723	604,238	347,500
Number of shares for the computation of diluted EPS	29,148,108	29,615,466	28,997,866
Diluted EPS income / (loss) (in Euros)	€ (0.06)	€ 0.05	€ (0.01)

FAIR VALUE OF FINANCIAL INSTR_3

FAIR VALUE OF FINANCIAL INSTRUMENTS - Schedule of Fair Value Measurement Inputs Level 1 (Details) - EUR (€) € in Thousands	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018	Dec. 31, 2017
Assets:
Cash and cash equivalents	€ 24,696	€ 20,886	€ 19,464	€ 20,004
Liabilities:
Short-term borrowings	2,638	3,513
Long-Term Debt	5,675	1,420
Fair Value, Inputs, Level 1 [Member]
Assets:
Cash and cash equivalents	24,696	20,886
Liabilities:
Short-term borrowings	2,638	3,513
Long-Term Debt	€ 5,675	€ 1,420

CONCENTRATION OF CREDIT RISK (D

CONCENTRATION OF CREDIT RISK (Details) - EUR (€) € in Millions	Dec. 31, 2020	Dec. 31, 2019
CONCENTRATION OF CREDIT RISK
Allowance for doubtful accounts receivable	€ 0.7	€ 1.5

SEGMENT INFORMATION (Details)

SEGMENT INFORMATION (Details)	12 Months Ended
	Dec. 31, 2020segment
SEGMENT INFORMATION
Reportable segments	3

SEGMENT INFORMATION - Reconcili

SEGMENT INFORMATION - Reconciliation of Operating Profit (Loss) From Segments to Consolidated (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
SEGMENT INFORMATION
Segment operating income (loss)	€ 269	€ 2,201	€ (1,315)
Financial income (expense), net	(98)	(146)	797
Foreign Currency exchange (losses) gains, net	(1,359)	136	538
Total	(516)	(679)	(358)
Net income (loss)	€ (1,704)	€ 1,512	€ (338)

SEGMENT INFORMATION - Schedule

SEGMENT INFORMATION - Schedule of Segment Reporting Information By Segment (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Revenues	€ 41,662	€ 44,912	€ 39,183
Cost of sales	(23,283)	(23,909)	(22,266)
Gross profit	18,379	21,002	16,917
Research and development expenses	(4,496)	(3,728)	(4,088)
Selling and marketing expenses	(9,279)	(10,850)	(10,551)
General and administrative expenses	(4,335)	(4,224)	(3,593)
Segment operating income (loss)	269	2,201	(1,315)
Total Assets	55,193	53,068
Goodwill	2,412	2,412
Product
Revenues	41,649	44,859	39,163
RPP's and leases
Revenues	4,745	5,747	5,086
Cost of sales	(2,601)	(3,000)	(2,557)
Spare parts and services
Revenues	9,382	9,001	9,007
Cost of sales	(5,732)	(5,467)	(5,655)
FDA [Member]
Revenues	41,662	44,912	39,183
Cost of sales	(23,283)	(23,909)	(22,266)
Gross profit	18,379	21,002	16,917
Research and development expenses	(4,496)	(3,728)	(4,088)
Selling and marketing expenses	(9,279)	(10,850)	(10,551)
General and administrative expenses	(4,335)	(4,224)	(3,593)
Total expenses	(18,110)	(18,802)	(18,232)
Segment operating income (loss)	269	2,201	(1,316)
Total Assets	55,193	53,068	48,740
Capital expenditures	2,011	1,532	1,928
Long-lived assets	9,801	10,971	8,013
Goodwill	2,412	2,412	2,412
FDA [Member] | Product
Revenues	27,523	30,111	25,070
FDA [Member] | RPP's and leases
Revenues	4,745	5,747	5,086
FDA [Member] | Spare parts and services
Revenues	9,382	9,001	9,007
FDA [Member] | Product and Services, Excluding Other
Revenues	41,649	44,859	39,163
FDA [Member] | Other revenues
Revenues	12	52	19
Operating Segments | High Intensity Focused Ultrasound (HIFU)
Revenues	11,438	14,144	11,044
Cost of sales	(5,144)	(6,152)	(5,312)
Gross profit	6,293	7,991	5,732
Research and development expenses	(2,583)	(1,962)	(2,394)
Selling and marketing expenses	(3,151)	(4,402)	(4,628)
General and administrative expenses	(1,005)	(1,168)	(1,036)
Total expenses	(6,738)	(7,533)	(8,057)
Segment operating income (loss)	(445)	459	(2,325)
Total Assets	16,279	16,665	13,648
Capital expenditures	1,144	915	1,154
Long-lived assets	3,706	4,096	2,855
Goodwill	645	645	645
Operating Segments | High Intensity Focused Ultrasound (HIFU) | Product
Revenues	6,000	8,311	5,494
Operating Segments | High Intensity Focused Ultrasound (HIFU) | RPP's and leases
Revenues	3,594	4,162	3,750
Operating Segments | High Intensity Focused Ultrasound (HIFU) | Spare parts and services
Revenues	1,831	1,618	1,780
Operating Segments | High Intensity Focused Ultrasound (HIFU) | Product and Services, Excluding Other
Revenues	11,425	14,092	11,025
Operating Segments | High Intensity Focused Ultrasound (HIFU) | Other revenues
Revenues	12	52	19
Operating Segments | Urology Devices and Services (ESWL)
Revenues	12,882	14,190	14,480
Cost of sales	(7,232)	(7,816)	(8,178)
Gross profit	5,649	6,374	6,302
Research and development expenses	(1,555)	(1,394)	(1,410)
Selling and marketing expenses	(2,052)	(2,441)	(2,357)
General and administrative expenses	(964)	(904)	(731)
Total expenses	(4,572)	(4,738)	(4,498)
Segment operating income (loss)	1,078	1,635	1,804
Total Assets	15,567	15,892	16,700
Capital expenditures	309	298	451
Long-lived assets	2,466	4,448	3,697
Goodwill	496	450	403
Operating Segments | Urology Devices and Services (ESWL) | Product
Revenues	6,248	6,715	7,069
Operating Segments | Urology Devices and Services (ESWL) | RPP's and leases
Revenues	927	1,426	1,254
Operating Segments | Urology Devices and Services (ESWL) | Spare parts and services
Revenues	5,707	6,048	6,157
Operating Segments | Urology Devices and Services (ESWL) | Product and Services, Excluding Other
Revenues	12,882	14,190	14,480
Operating Segments | Distribution (DISTRIB) Division [Member]
Revenues	17,342	16,578	13,657
Cost of sales	(10,906)	(9,941)	(8,775)
Gross profit	6,436	6,637	4,882
Research and development expenses	(358)	(372)	(285)
Selling and marketing expenses	(4,076)	(4,008)	(3,566)
General and administrative expenses	(900)	(854)	(580)
Total expenses	(5,335)	(5,233)	(4,431)
Segment operating income (loss)	1,102	1,404	451
Total Assets	20,795	16,500	13,149
Capital expenditures	557	319	324
Long-lived assets	3,628	2,427	1,462
Goodwill	1,271	1,317	1,364
Operating Segments | Distribution (DISTRIB) Division [Member] | Product
Revenues	15,274	15,084	12,505
Operating Segments | Distribution (DISTRIB) Division [Member] | RPP's and leases
Revenues	224	158	82
Operating Segments | Distribution (DISTRIB) Division [Member] | Spare parts and services
Revenues	1,844	1,335	1,070
Operating Segments | Distribution (DISTRIB) Division [Member] | Product and Services, Excluding Other
Revenues	17,342	16,578	13,657
Reconciling Items | EDAP Technomed Co Ltd. [Member]
General and administrative expenses	(1,465)		(1,247)
Total expenses	(1,465)		(1,247)
Segment operating income (loss)	(1,465)		(1,247)
Total Assets	€ 2,551	€ 4,012	€ 5,243

VALUATION ACCOUNTS (Details)

VALUATION ACCOUNTS (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]
Balance	€ 14,977	€ 14,553	€ 14,266
Charges to costs and expenses	596	859	515
Deductions: write-off and others	(65)	(435)	(228)
Balance	15,508	14,977	14,553
SEC Schedule, 12-09, Allowance, Credit Loss [Member]
Balance	1,490	1,404	1,029
Charges to costs and expenses	90	94	365
Deductions: write-off and others	(858)	(9)	10
Balance	722	1,490	1,404
SEC Schedule, 12-09, Reserve, Inventory [Member]
Balance	1,085	974	723
Charges to costs and expenses	651	333	355
Deductions: write-off and others	(172)	(223)	(104)
Balance	1,563	1,085	974
SEC Schedule, 12-09, Reserve, Warranty [Member]
Balance	370	548	449
Charges to costs and expenses	266	131	433
Deductions: write-off and others	(268)	(308)	(334)
Balance	€ 368	€ 370	€ 548

SUPPLEMENTAL DISCLOSURES OF C_3

SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION (Details) - EUR (€) € in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION
Income taxes paid (refunds received)	€ 377	€ 289	€ 407
Interest paid	124	87	49
Interest received	10	17	12
Financing lease obligations incurred	192	203	427
Operating lease obligations incurred	317	3,483
Operating cash flow used in operating leases	941
Operating cash flow used in finance leases	18
Financing cash flow used in finance leases	€ 321	€ 396	€ 358

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) € in Thousands	Dec. 31, 2020EUR (€)	Apr. 22, 2020JPY (¥)	Dec. 31, 2019EUR (€)	Aug. 19, 2019JPY (¥)	Aug. 02, 2019USD ($)	Mar. 27, 2019MYR (RM)
Related Party Transaction [Line Items]
Operating lease, liability | €			€ 2,684
Loans Payable [Member]
Related Party Transaction [Line Items]
Loan amount | €	€ 6,000
EDAP Technomed Co Ltd. [Member] | JAPAN
Related Party Transaction [Line Items]
Loan amount | ¥		¥ 50,000,000
EDAP Technomed Co Ltd. [Member] | JAPAN | Loans Payable [Member]
Related Party Transaction [Line Items]
Loan amount | ¥				¥ 80,000,000
EDAP Technomed Sdn Bdh [Member] | Malaysia | Loans Payable [Member]
Related Party Transaction [Line Items]
Loan amount | RM						RM 65,464.85
EDAP Technomed Inc. [Member] | Car Lease Required Personal Warranty [Member] | President [Member]
Related Party Transaction [Line Items]
Operating lease, liability | $					$ 28,756.44